Subject Index

A

Aclarubicin
given as continuous infusion in non-small cell bronchogenic carcinoma, 1327
phase II evaluation of, in advanced breast cancer: a Southeastern Cancer Study Group trial, 1029
phase II study of, in patients with lymphoma, 1315
phase II study of, in previously untreated patients with advanced soft tissue sarcoma: a Southeastern Cancer Study Group trial, 725
phase II study of, in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group study, 451
phase II study of, in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study, 1033
Adenocarcinoma *see* Cancer, adenocarcinoma
Adrenal suppression in breast cancer patients, relation with plasma levels of medroxyprogesterone acetate, 977
Adverse effects, animals
arterial drug infusion with extracorporeal removal: internal carotid carmustine in the rhesus monkey, 293
cold protection and heat enhancement of doxorubicin skin toxicity in the mouse, 431
Adverse effects, man
acute cardiac failure from doxorubicin cardiotoxicity provoked in relation to second-look laparotomy, 730
acute ECG changes during cyclophosphamide infusion in a patient with bronchogenic carcinoma, 734
acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethecin administration, 342
allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies, 439
aminoglutethimide-induced hematologic toxicity: worldwide experience, 1003
antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research, 1353
antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting, 109
brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia, 1005
cisplatin neurotoxicity: failure to demonstrate vitamin B_{12} inactivation, 453
clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a Leukemia Intergroup report, 240
clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants, 377
coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon, 315
comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis, 1301
disturbing central nervous system complications following combination chemotherapy and prophylactic whole-brain irradiation in patients with small cell lung cancer, 1429
dynamic left ventricular outflow obstruction and myocardial infarction following doxorubicin administration in a woman affected by unsuspected hypertrophic cardiomyopathy, 241
effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura, 565
evaluation of a combination antiemetic regimen including iv high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens, 909
excessive tissue ulceration due to apparent sensitivity reactions to mitomycin, 925
failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine, 373
fatal pneumothorax following bleomycin and other cytotoxic drugs, 344
hemolytic anemia associated with antineoplastic agents, 777
hyperphosphatemic renal failure following treatment of acute nonlymphatic leukemia, 563
hypersensitivity reactions to amsacrine, 199
hypoglycemia: not an important side effect of mitoguazone, 1340
immediate hypersensitivity to mannitol: a potential cause of apparent hypersensitivity to cisplatin, 562
liver enzyme abnormalities after poly ICLC infusions, 1342
local toxicity from iv administration of Baker's antifol, 735
localized subcutaneous toxicity following bleomycin administration, 561
N-methylformamide-induced hypophosphatemia, 343
metoclopramide in vincristine-induced ileus, 1309
pancreatitis following cisplatin: a case report, 236
parkinsonism following iv administration of high-dose metoclopramide used as an antiemetic agent during cancer chemotherapy, 341
possible interactions between warfarin and antineoplastic drugs, 244
prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon, 743
salivary hyperamylasemia after L-asparaginase therapy, 1437
severe central nervous system toxicity from high-dose cytarabine: expressive aphasia occurring after the second day of treatment, 313
skeletal muscle biopsies in patients treated with doxorubicin, 1342
sister chromatid exchanges induced by cancer chemotherapeutic agents in vitro and in vivo: consideration of the hazard of drugs as possible mutagens and carcinogens causing

second malignancies, 505
successful continuation of cisplatin therapy after partial recovery from acute renal failure, 731
tastes associated with parenteral chemotherapy for breast cancer, 1249
vinca alkaloid-induced cardiovascular autonomic neuropathy, 149
Aerodigestive cancer *see* Cancer, aerodigestive
Alizapride, compared to metoclopramide, for efficacy against cisplatin-induced emesis, 1301
Allopurinol, and altered plasma kinetics of 5-FU at high dosage in rat and man, 133
Aminoglutethimide
-induced hematologic toxicity: worldwide experience, 1003
influence of, on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol, 85
4-Amino-*N*-(2′-aminophenyl)benzamide, a new compound preferentially active in slowly growing tumors: synthesis, toxicity, and therapeutic efficacy of, 1415
Amsacrine
m-AMSA and *m*-AMSA lactate, phase II study with, in refractory lymphomas, 965
combined with 5-azacitidine, sequentially administered, in refractory adult acute leukemia: a phase I–II trial of the Southeastern Cancer Study Group, 807
combined with high-dose cytarabine, in acute leukemia, 1001, 1447
compared to cyclophosphamide, doxorubicin, and cisplatin (CAP), phase II trial of, in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study, 189
hypersensitivity reactions to, 199
Pediatric Oncology Group phase II trial of, in children with solid tumors, 335
phase II evaluation of, in small cell lung cancer: a Southeastern Cancer Study Group trial, 333
phase II study of, in gastric carcinoma: a Southwest Oncology Group study, 557
in refractory acute leukemia, 787
Anal cancer *see* Cancer, anal
Animal experiments *see also* Adverse effects, animals; Tumor systems, animals
altered plasma kinetics of 5-FU at high dosage in rat and man, 133
circadian rhythm in tolerance of mice for etoposide, 1443
pharmacokinetics of hexamethylmelamine administered via the ip route in an oil emulsion vehicle, 657
L-Asparaginase, salivary hyperamylasemia after treatment with, 1437
Aspirin, and antiproliferative activity of human interferon, 97
5-Azacitidine
administered by continuous infusion, combined with etoposide, therapy for chronic myelogenous leukemia in blast crisis with: a Cancer and Leukemia Group B study, 1027
combined with amsacrine, sequentially administered, in refractory adult acute leukemia: a phase I–II trial of the Southeastern Cancer Study Group, 807

B

Bacillus Calmette-Guérin (BCG), intravesical administration of, in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial, 47
Baker's antifol, local toxicity from iv administration of, 735
4,6-Benzylidene-α-D-glucose, antitumor activity of, 533
Biochemical modulation, application of, with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy, 421
Biological response modifiers
applicability of phase I trial results in the design of phase II and III biological response modifier trials, 1171
assessment of biological responses: what to measure and when, 1165
clinical trials: general discussion, 1175
design of clinical trials with, 1161
1,25-dihydroxyvitamin D_3: in vivo and in vitro effects on human preleukemic and leukemic cells, 1399
effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors, 285
liver enzyme abnormalities after poly ICLC infusions, 1342
Biometric issues
factorial designs for randomized clinical trials, 1055
panel discussion, 1079
regression models for prognostic prediction: advantages, problems, and suggested solutions, 1071
response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy, 1049
role of mathematical modeling in protocol formulation in cancer chemotherapy, 1041
tree-structured survival analysis, 1065
Bisantrene
phase I study of, in acute nonlymphoblastic leukemia, 703
phase II evaluation of, in metastatic breast cancer, 337
phase II evaluation of, in patients with advanced non-small cell lung carcinoma, 209
phase II evaluation of, in patients with advanced renal cell carcinoma, 727
***trans*-Bis(salicylaldoximato)copper(II),** antitumor activity of, 1021
Bladder cancer *see* Cancer, bladder
Bleomycin
combined with cisplatin, alternated with sequential methotrexate and 5-FU plus leucovorin rescue, in patients with head and neck cancer, 1015
combined with cisplatin and vinblastine, in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group, 821
combined with etoposide, carmustine, and methotrexate with leucovorin rescue, as re-treatment for unfavorable non-Hodgkin's lymphoma, 783
combined with etoposide and cisplatin, as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma, 483
combined with mitoguazone, methotrexate, and cisplatin as chemotherapy for esophageal cancer, 21
combined with mitomycin and cisplatin, for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group, 903
fatal pneumothorax following, 344
localized subcutaneous toxicity following administration of, 561
Bone marrow plasma cell labeling index, and rate of M-

component changes in 25 patients with multiple myeloma treated with peptichemio, 971
Bone marrow transplantation
autologous, with marrow decontaminated by immunotoxin T 101, in the treatment of leukemia and lymphoma: first clinical observations, 953
autologous, treatment of metastatic malignant melanoma with intensive melphalan and, 473
clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants, 377
Bone scanning, with ^{99m}Tc methylene diphosphonate, role of, in the management of lymphoma, 1347
Brain cancer *see* Cancer, brain
Breast cancer *see* Cancer, breast
Bronchogenic carcinoma *see* Cancer, lung

C

Cancer *see also* Leukemia
adenocarcinoma
advanced, long-term, ambulatory, continuous iv infusion of 5-FU for the treatment of, 13
advanced, phase I–II clinical trial of thymidine, 5-FU, and PALA given in combination for, 611
of unknown primary origin: treatment with vindesine and doxorubicin, 591
aerodigestive, advanced upper, phase II trial of diaziquone in, 141
anal, squamous cell, effectiveness of cisplatin in the treatment of, 891
bladder
invasive urothelial, combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with, 33
recurrent superficial, intravesical administration of bacillus Calmette-Guérin in patients with: report of a prospective, randomized trial, 47
transitional cell, phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with: a Southwest Oncology Group study, 189
brain
inability of dimethyl sulfoxide to increase brain uptake of water-soluble compounds: implications to chemotherapy for, 305
malignant glioblastoma, combination of lomustine and cimetidine in the treatment of a patient with: a case report, 733
malignant primary, phase II trial of mitoguazone in, 329
recurrent, evaluation of cisplatin in children with, 911
relapsed primary, high-dose etoposide in the treatment of, 603
breast
advanced, phase II evaluation of aclarubicin in a Southeastern Cancer Study Group trial, 1029
advanced, phase II study of elliptinium in, 707
advanced, phase II trial of carboplatin in: a Cancer and Leukemia Group B study, 919
advanced, phase II trial of 4′-deoxydoxorubicin in patients with, 1319
advanced, phase II trial of α-lymphoblastoid interferon given weekly as treatment of, 547
advanced, randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with, 355
advanced, trilostane therapy for, 351
endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with, 977
endometrial adenocarcinoma in patients receiving antiestrogens, 237
metastatic, comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with, 633
metastatic, phase II evaluation of bisantrene in, 337
metastatic, tamoxifen therapy in premenopausal women with, 363
previously treated, mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with, 755
tastes associated with parenteral chemotherapy for, 1249
cervical
advanced, phase II study of spirogermanium in patients with, 457
advanced squamous, bleomycin, mitomycin, and cisplatin therapy for: a phase II study of the Northern California Oncology Group, 903
recurrent, clinical evaluation of high-dose cytarabine and cisplatin in, 1023
refractory, continuous-infusion vindesine in: a phase II trial, 1317
colon
adenocarcinoma, cisplatin plus 5-FU for the treatment of, 1359
adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with: a Southwest Oncology Group phase II pilot study, 129
cellular basis for the inefficacy of 5-FU in, 1391
human adenocarcinoma cells, selective cytotoxicity of 5-hydroxyuridine for, 845
human cell line, sequence-dependent synergism between dichloromethotrexate and cisplatin in, 279
phase II trial of diaziquone in patients with, 215
colorectal
adenocarcinoma, tamoxifen therapy and: a Southwest Oncology Group study, 113
advanced, 5-FU infusion in: a comparison of three dose schedules, 739
advanced, phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with, 179
advanced, phase II trial of 4′-epi-doxorubicin in: a Northern California Oncology Group study, 143
advanced measurable, Eastern Cooperative Oncology Group phase II studies in: razoxane, Yoshi-864, piperazinedione, and lomustine, 543
metastatic, treatment of, with cisplatin and 5-FU, 123
metastatic, without previous systemic treatment, phase II trial of high-dose recombinant leukocyte alpha-2 interferon for, 185
untreated, mitomycin and methotrexate: negative experience in, 223
endometrial
adenocarcinoma, in breast cancer patients receiving antiestrogens, 237

adenocarcinoma, mitoxantrone in: a Southwest Oncology Group study, 1329
advanced, cisplatin, doxorubicin, and cyclophosphamide chemotherapy for, 465
advanced, treatment of, with doxorubicin and cisplatin: effects on both untreated and previously treated patients, 539
esophageal
advanced epidermoid, carboplatin in the treatment of, 1305
chemotherapy for, with mitoguazone, methotrexate, bleomycin, and cisplatin, 21
squamous carcinoma of, phase II evaluation of cisplatin in: a Southeastern Cancer Study Group trial, 1457
gastric
advanced, chemotherapy in, 927
advanced, cisplatin in the treatment of: a phase II study, 449
phase II study of amsacrine in: a Southwest Oncology Group study, 557
phase II trial of epirubicin in, 1275
gastrointestinal tract
adenocarcinoma of upper, phase II trial of carboplatin in patients with, 1453
advanced leiomyosarcoma, doxorubicin, dacarbazine, vincristine, and cyclophosphamide in the treatment of, 443
germ cell
advanced, etoposide and very high-dose cisplatin: salvage therapy for patients with, 259
refractory, phase II trial of 1,2-diaminocyclohexane-(4-carboxyphthalato)platinum(II) in patients with, 459
refractory, phase II trial of mitoguazone in patients with, 461
refractory, phase II trial of mitoxantrone in: a trial of the Southeastern Cancer Study Group, 1455
gestiochoriocarcinoma, pharmacokinetics of etoposide in, 69
head and neck
advanced, improved control in, with simultaneous radiation and cisplatin/5-FU chemotherapy, 933
advanced, phase II trial of 4′-epi-doxorubicin in, 125
advanced salivary gland, supporting evidence for an active treatment program for, 319
advanced squamous cell, comparison of methotrexate and cisplatin for patients with: a Southwest Oncology Group study, 577
recurrent squamous cell, phase I–II trial with cisplatin and 5-FU in: an effective outpatient schedule, 961
squamous cell, alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with, 1015
squamous cell, methotrexate: bioavailability and pharmacokinetics, 833
Hodgkin's disease
deep venous thrombosis during therapy for, 1011
refractory, treatment of, with teniposide, cisplatin, hexamethylmelamine, and prednisolone: Cancer and Leukemia Group B trial 8171, 719
large bowel, advanced, phase II trial of diaziquone in previously treated and untreated patients: a Southwest Oncology Group study, 709
lung
acute ECG changes during cyclophosphamide infusion in a patient with, 734
advanced non-small cell, aclarubicin given as continuous infusion in, 1327
advanced non-small cell, comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of, 945
advanced non-small cell, phase II evaluation of bisantrene in patients with, 209
advanced non-small cell, phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of: an Eastern Cooperative Oncology Group study, 1033
advanced non-small cell, phase II study of recombinant alpha interferon in the treatment of, 1031
advanced non-small cell, phase II trial of 4′-deoxydoxorubicin in, 1337
advanced non-small cell, phase II trial of etoposide, vincristine, and high-dose cisplatin in, 1335
advanced small cell, phase II study of aclarubicin and diaziquone in the treatment of: an Eastern Cooperative Oncology Group study, 451
inoperable, combined-modality treatment of (iv immunotherapy, chemotherapy, and radiotherapy), 251
inoperable nonmetastatic squamous cell, combined chemotherapy (vindesine, lomustine, cisplatin, and cyclophosphamide) and radical radiotherapy in, 469
metastatic bronchioloalveolar cell, phase II trial of 5-FU, vincristine, and mitomycin (FOMi) in: a Southwest Oncology Group study, 1313
non-small cell, cisplatin bolus and 5-FU infusion chemotherapy for, 1253
non-small cell, randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with, with an analysis of methods of response assessment, 387
non-small cell, treatment of, with vinblastine and mitomycin: a Southwest Oncology Group study, 583
phase II clinical trial of diaziquone in, 921
refractory small cell, cisplatin and etoposide combination chemotherapy for, 479
refractory small cell, multicenter phase II trial of etoposide in, 127
regional stage III unresectable non-small cell, combination chemotherapy followed by radiation therapy in patients with, 587
small cell, carboplatin in the treatment of, 43
small cell, cyclic alternating chemotherapy for, 1241
small cell, disturbing central nervous system complications following combination chemotherapy and prophylactic whole-brain irradiation in patients with, 1429
small cell, effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with: a randomized trial, 167
small cell, etoposide and cisplatin salvage chemotherapy for, 369
small cell, intensive alternating chemotherapy regimen in, 161
small cell, intensive induction treatment of, with cyclophosphamide, methotrexate, and etoposide, 1007
small cell, phase II evaluation of amsacrine in: a Southeastern Cancer Study Group trial, 333
small cell, probable cure of, by etoposide, 235
small cell, treatment of, with 6-mercaptopurine: a phase II study, 555

small cell anaplastic, intensive induction chemotherapy for, 571
stage IV non-oat cell, pilot study of multiple-fraction daily radiotherapy alternating with chemotherapy in patients with, 25
lymphoma
advanced, phase II study of aclarubicin in patients with, 1315
allergic reactions to teniposide in patients with, 439
autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of: first clinical observations, 953
refractory, phase II study of amsacrines (*m*-AMSA and *m*-AMSA lactate) in, 965
relapsed non-Hodgkin's, treatment of, with a combination of hydroxyurea, ifosfamide, and etoposide, 225
role of ^{99m}Tc methylene diphosphonate bone imaging in the management of, 1347
unfavorable non-Hodgkin's, etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as retreatment for, 783
melanoma
advanced malignant, phase II study of mitolactol in, 723
advanced malignant, phase II trial of 4-demethoxydaunorubicin in patients with, 915
advanced malignant, phase II trial of gallium nitrate in patients with, 1019
advanced malignant, single-dose dacarbazine and dactinomycin in, 39
disseminated malignant, phase II study of mitomycin in, 1451
metastatic, cisplatin, vinblastine, and bleomycin in the treatment of: a phase II study of the Southeastern Cancer Study Group, 821
metastatic, clinical-biologic patterns of, and their effect on treatment, 397
metastatic malignant, lomustine, vincristine, and procarbazine in the treatment of, 941
metastatic malignant, phase II study of mitolactol in, 65
metastatic malignant, phase II trial of lymphoblastoid interferon in, 813
metastatic malignant, treatment of, with intensive melphalan and autologous bone marrow transplantation, 473
mesothelioma
diffuse malignant pleural, randomized trial of doxorubicin versus cyclophosphamide in, 1431
intracavitary cisplatin chemotherapy for, 205
malignant, phase II trial of high-dose cisplatin in patients with, 711
myeloma
advanced multiple, phase II trial of mitoxantrone in: a Southwest Oncology Group study, 1321
multiple, phase II study of rDNA human alpha-2 interferon in, 495
multiple, rate of M-component changes and plasma cell labeling index in 25 patients with, treated with peptichemio, 971
multiple, treatment of, with recombinant human leukocyte A interferon, 1433
resistant multiple, diaziquone for, 331
nasopharyngeal, cooperative trial of immunotherapy for, with transfer factor from donors with Epstein-Barr virus antibody activity, 761
neuroblastoma
allergic reactions to teniposide in patients with, 439
ultrafiltrate and total platinum in plasma and cerebrospinal fluid in a patient with, 1441
ovarian
advanced, activity of JM9 in: a phase I-II trial, 409
advanced, phase II study of 4-demethoxydaunorubicin in, 559
advanced, phase II study of 5-day infusion of vinblastine in patients with, 229
advanced, phase II trial of diaziquone in, 339
advanced, recombinant leukocyte alpha interferon in, 895
advanced, response to the agonist D-Trp-6-LHRH, 1341
peptichemio in pretreated patients with, 17
pharmacokinetics of teniposide in patients with, 73
previously treated with chemotherapy, phase II study of low-dose mitomycin in patients with, 1271
refractory, continuous-infusion spirogermanium for the treatment of: a phase II trial, 139
six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU, CHAMP-5) for: alternating sequences of combination regimens, 689
stage III and IV, comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for, 1243
pancreatic
adenocarcinoma, phase II evaluation of melphalan in, 917
advanced measurable, phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and β-2′-deoxythioguanosine as single agents against, 713
advanced measurable adenocarcinoma, phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against, 417
prostatic
advanced hormone-refractory, continuous infusion of vinblastine for, 885
hormone-resistant metastatic, randomized trial of combination chemotherapy in, 105
renal, advanced, phase II study of human lymphoblastoid interferon in patients with, 817
renal cell
advanced, phase II evaluation of bisantrene in patients with, 727
advanced, phase II trial of elliptinium in, 901
failure of 5-day vinblastine infusion in the treatment of patients with, 227
interferon and doxorubicin in, 721
metastatic, phase II study of thymosin fraction 5 in the treatment of, 137
treatment of, with α(human leukocyte) interferon and vinblastine in combination: a phase I-II trial, 263
sarcoma
advanced, phase II trial of mitoxantrone in: a Southwest Oncology Group study, 231
advanced gastrointestinal leiomyosarcoma, doxorubicin, dacarbazine, vincristine, and cyclophosphamide in the treatment of, 443
advanced osteogenic, phase II study of cisplatin in, 211
advanced osteosarcoma, high-dose ifosfamide in, 115

advanced soft tissue, phase II study of aclarubicin in previously untreated patients with: a Southeastern Cancer Study Group trial, 725
advanced soft tissue and bony, phase II study of diaziquone in: a Southwest Oncology Group study, 1035
childhood rhabdomyosarcoma, combination of dacarbazine and doxorubicin in the treatment of, 999
childhood rhabdomyosarcoma, melphalan: a potential new agent in the treatment of, 91
leiomyosarcoma, increased cytosol glucocorticoid receptor content of, 907
previously treated metastatic, phase II trial of ifosfamide with mesna in, 499
testicular nonseminoma, etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of, 483
thymoma, invasive, cisplatin-containing chemotherapy in the treatment of: report of five cases, 695

Cancer clinical trials *see also* Biological response modifiers, Biometric issues, Quality assurance
analysis and interpretation of the comparison of survival by treatment outcome variables, 1139
eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in, 1107
influence of measurement error on response rates, 1127
measuring quality of life: risks and benefits, 1115
methodologic guidelines for reports of, 1
panel discussion: general issues, 1133
phase II randomized, 1375
phase III, size of, 1087
phase III studies of combination chemotherapies, an efficient design for, 1147
policies for interim analysis and interim reporting of results, 1101
randomized, physician participation in, 1095
symposium on methodology and quality assurance in, 1039

CAP (cyclophosphamide, doxorubicin, and cisplatin)
combination chemotherapy followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer, 587
phase II trial of, versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study, 189
supporting evidence for an active treatment program for advanced salivary gland carcinomas, 319

Carboplatin
a new platinum analog in the treatment of epidermoid carcinoma of the esophagus, 1305
phase II trial of, in advanced breast carcinoma: a Cancer and Leukemia Group B study, 919
phase II trial of, in patients with adenocarcinomas of the upper gastrointestinal tract, 1453
a very active new cisplatin analog in the treatment of small cell lung cancer, 43

Carmustine
arterial drug infusion with extracorporeal removal: internal carotid carmustine in the rhesus monkey, 293
combined with etoposide, bleomycin, and methotrexate with leucovorin rescue, as re-treatment for unfavorable non-Hodgkin's lymphoma, 783

CAV (cyclophosphamide, doxorubicin, and vincristine), combined with VHM (etoposide, hexamethylmelamine, and methotrexate), in small cell carcinoma of the lung, 161

Cell culture studies *see also* In vitro studies
cellular basis for the inefficacy of 5-FU in human colon carcinoma, 1391
clonogenic and nonclonogenic in vitro chemosensitivity assays, 615
cold protection and heat enhancement of doxorubicin skin toxicity in the mouse, 431
competitive protein-binding assay for trimetrexate, 641
cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs, 515
deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells, 851
1,25-dihydroxyvitamin D_3: in vivo and in vitro effects on human preleukemic and leukemic cells, 1399
double labeling of human leukemic cells using ^{3}H-cytarabine and monoclonal antibody against bromodeoxyuridine, 195
effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex, 875
enhancement of the antiproliferative activity of human interferon by polyamine depletion, 97
factors modifying cytotoxicity induced by 5-FU and hydroxyurea, 993
increased cytosol glucocorticoid receptor content of leiomyosarcoma, 907
increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards, 677
promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs, 673
selective cytotoxicity of 5-hydroxyuridine for human colon adenocarcinoma cells, 845
sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line, 279
sister chromatid exchanges induced by cancer chemotherapeutic agents in vitro and in vivo: consideration of the hazard of drugs as possible mutagens and carcinogens causing second malignancies, 505
vitamin K_3 inhibition of malignant murine cell growth and human tumor colony formation, 527

Cervical cancer *see* Cancer, cervical

CF (cyclophosphamide and 5-FU), compared with DC (doxorubicin and lomustine) in randomized trial of combination chemotherapy for hormone-resistant metastatic prostate carcinoma, 105

CFP (cyclophosphamide, 5-FU, and prednisone), randomized clinical trial of, with or without tamoxifen in postmenopausal women with advanced breast cancer, 355

CHAMP-5 (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU), for ovarian carcinoma: alternating sequences of combination regimens, 689

Children
with acute lymphoblastic leukemia, prognostic implications of blast cell morphology in: a report from the Childrens Cancer Study Group, 1211
with acute nonlymphocytic leukemia in relapse, cyclophosphamide/etoposide: effective reinduction therapy for, 887
coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon, 315
with leukemia, phase I evaluation of β-2′-deoxythioguanosine in, 699
with neuroblastoma and lymphoid malignancies, allergic re-

actions to teniposide in, 439
phase I clinical evaluation of diaziquone in childhood cancer, 323
phase I trial of mitoxantrone in, 403
with recurrent brain tumors, evaluation of cisplatin in, 911
with refractory childhood malignancies, phase II trial of dianhydrogalactitol in the treatment of: a report from the Childrens Cancer Study Group, 1331
with rhabdomyosarcoma, combination of dacarbazine and doxorubicin in the treatment of, 999
with rhabdomyosarcoma, melphalan: a potential new agent in the treatment of, 91
with solid tumors, Pediatric Oncology Group phase II trial of amsacrine in, 335
tolerance to antineoplastic agents in, 1263
Chlorozotocin, low-dose and high-dose, phase II trials of, as single agents against advanced measurable adenocarcinoma of the pancreas, 417
Cimetidine, combined with lomustine, in the treatment of a patient with malignant glioblastoma: a case report, 733
Circadian rhythm, in tolerance of mice for etoposide, 1443
CISCA (cyclophosphamide, doxorubicin, and cisplatin), combined intravenous and intra-arterial, in the management of select patients with invasive urothelial tumors, 33
Cisplatin
-based chemotherapy regimens, evaluation of a combination antiemetic regimen including iv high-dose metoclopramide, dexamethasone, and diphenhydramine in, 909
bolus, combined with 5-FU infusion, for non-small cell lung cancer, 1253
combined with bleomycin, alternated with sequential methotrexate and 5-FU plus leucovorin rescue, in patients with head and neck cancer, 1015
combined with bleomycin and mitomycin, for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group, 903
combined with cyclophosphamide, compared to hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination, as initial chemotherapy for stage III and IV ovarian carcinomas, 1243
combined with cyclophosphamide and doxorubicin (CAP), as chemotherapy for advanced endometrial carcinoma, 465
combined with cyclophosphamide and doxorubicin (CAP), compared to amsacrine, phase II trial of, in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study, 189
combined with cyclophosphamide and doxorubicin (CAP), followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer, 587
combined with cyclophosphamide and doxorubicin (CAP), supporting evidence for an active treatment program for advanced salivary gland carcinomas, 319
combined with cyclophosphamide and doxorubicin (CISCA), intravenous and intra-arterial, in the management of select patients with invasive urothelial tumors, 33
combined with dichloromethotrexate, sequence-dependent synergism in a human colon carcinoma cell line, 279
combined with etoposide, chemotherapy for refractory small cell carcinoma of the lung, 479
combined with etoposide, salvage chemotherapy for small cell lung cancer, 369
combined with etoposide, with or without bleomycin, as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma, 483
combined with 5-FU, phase I–II trial of, in recurrent head and neck cancer: an effective outpatient schedule, 961
combined with 5-FU and simultaneous radiation therapy, improved control in advanced head and neck cancer with, 933
combined with 5-FU, for the treatment of adenocarcinoma of the colon, 1359
combined with 5-FU, treatment of metastatic colorectal carcinoma with, 123
combined with hexamethylmelamine, cyclophosphamide, and doxorubicin, compared to cyclophosphamide plus cisplatin, as initial chemotherapy for stage III and IV ovarian carcinomas, 1243
combined with hexamethylmelamine, doxorubicin, cyclophosphamide, methotrexate, and 5-FU (CHAMP-5), for ovarian carcinoma: alternating sequences of combination regimens, 689
combined with high-dose cytarabine, clinical evaluation of, in recurrent cervical carcinoma, 1023
combined with high-dose cytarabine, phase I study of, in patients with advanced malignancy, 897
combined with mitoguazone, methotrexate, and bleomycin, chemotherapy for esophageal cancer with, 21
combined with teniposide, hexamethylmelamine, and prednisolone, treatment of refractory Hodgkin's disease with: Cancer and Leukemia Group B trial 8171, 719
combined with vinblastine, compared with vindesine plus cisplatin, randomized trial in patients with non-small cell lung cancer, with an analysis of methods of response assessment, 387
combined with vinblastine and bleomycin, in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group, 821
combined with vindesine, compared to vinblastine plus cisplatin, randomized trial in patients with non-small cell lung cancer, with an analysis of methods of response assessment, 387
combined with vindesine, compared to vindesine plus mitomycin, in the treatment of advanced non-small cell lung cancer, 945
combined with vindesine, lomustine, and cyclophosphamide (VCPC), and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung, 469
compared to methotrexate, for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study, 577
-containing chemotherapy in the treatment of invasive thymoma: report of five cases, 695
effect of, an organic ion transport in membrane vesicles from rat kidney cortex, 875
effectiveness of, in the treatment of anal squamous cell carcinoma, 891
evaluation of, in children with recurrent brain tumors, 911
excretion into human milk, 1387
high-dose, combined with etoposide and vincristine, phase II trial of, in advanced non-small cell lung cancer, 1335
high-dose, phase II trial of, in patients with malignant mesothelioma, 711
immediate hypersensitivity to mannitol: a potential cause of apparent hypersensitivity to, 562
-induced emesis, comparison of the antiemetic efficacy of two

high-dose benzamides, metoclopramide and alizapride, against, 1301
-induced neurotoxicity: failure to demonstrate vitamin B_{12} inactivation, 453
intracavitary chemotherapy for mesothelioma, 205
pancreatitis following: a case report, 236
phase II study of, in advanced osteogenic sarcoma, 211
phase II evaluation of, in squamous carcinoma of the esophagus: a Southeastern Cancer Study Group trial, 1457
successful continuation of, after partial recovery from acute renal failure, 731
time dependency in plasmatic protein binding of, 79
-treated cancer patients, antiemetic activity of two different high doses of metoclopramide in: a randomized double-blind trial of the Italian Oncology Group for Clinical Research, 1353
in the treatment of advanced gastric carcinoma: a phase II study, 449
very high-dose, combined with etoposide, salvage therapy for patients with advanced germ cell neoplasms, 259
Clonogenic and nonclonogenic in vitro chemosensitivity assays, 615
Colon cancer *see* Cancer, colon
Colorectal carcinoma *see* Cancer, colorectal
Combination chemotherapies, an efficient design for phase III studies of, 1147
Copper chelates, enhancement of tumorigenicity of B16 melanoma in heterogenetic mice by administration of, 1283
Cyclophosphamide
acute ECG changes during infusion in a patient with bronchogenic carcinoma, 734
combined with cisplatin, compared to hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination, as initial chemotherapy for stage III and IV ovarian carcinomas, 1243
combined with cisplatin and doxorubicin (CAP), chemotherapy for advanced endometrial carcinoma, 465
combined with cisplatin and doxorubicin (CAP), compared to amsacrine, phase II trial of, in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study, 189
combined with cisplatin and doxorubicin (CAP), followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer, 587
combined with cisplatin and doxorubicin (CAP), supporting evidence for an active treatment program for advanced salivary gland carcinomas, 319
combined with doxorubicin and cisplatin (CISCA), intravenous and intra-arterial, in the management of select patients with invasive urothelial tumors, 33
combined with doxorubicin, dacarbazine, and vincristine, in the treatment of advanced gastrointestinal leiomyosarcoma, 443
combined with doxorubicin and vincristine (CAV), alternated with etoposide, hexamethylmelamine, and methotrexate (VHM), in small cell carcinoma of the lung, 161
combined with doxorubicin and vincristine, alternated with mitomycin, methotrexate, and etoposide, for small cell carcinoma of the lung, 1241
combined with doxorubicin and vincristine, failure of scalp hypothermia to prevent hair loss from, 373
combined with etoposide, effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse, 887
combined with forphenicinol, effect of, on growth of and immunity to syngeneic murine tumors, 285
combined with 5-FU (CF), compared with doxorubicin and lomustine (DC), randomized trial of, in hormone-resistant metastatic prostate carcinoma, 105
combined with 5-FU and prednisone, randomized clinical trial of, with or without tamoxifen, in postmenopausal women with advanced breast cancer, 355
combined with hexamethylmelamine, doxorubicin, and cisplatin, compared to cyclophosphamide plus cisplatin, as initial chemotherapy for stage III and IV ovarian carcinomas, 1243
combined with hexamethylmelamine, doxorubicin, cisplatin, methotrexate, and 5-FU (CHAMP-5), for ovarian carcinoma: alternating sequences of combination regimens, 689
combined with methotrexate and etoposide, treatment of small cell bronchogenic carcinoma with, 1007
combined with methotrexate and 5-FU, tastes associated with parenteral chemotherapy for breast cancer, 1249
combined with vincristine and semustine, for small cell anaplastic carcinoma of the lung, 571
combined with vindesine, lomustine, and cisplatin (VCPC), and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung, 469
compared to doxorubicin, randomized trial of, in diffuse malignant pleural mesothelioma, 1431
effect of, on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura, 565
Cytarabine
acute nonlymphocytic leukemia induction chemotherapy, effectiveness in acute lymphocytic leukemia, 1439
combined with vincristine and prednisone, treatment of blast crisis of chronic myelogenous leukemia with, 923
combined with vindesine and prednisolone, treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating, 1297
high-dose, brachial plexus neuropathy following, in acute nonblastic leukemia, 1005
high-dose, clinical evidence of a cumulative effect of, on the cerebellum in patients with acute leukemia: a Leukemia Intergroup report, 240
high-dose, combined with amsacrine, in acute leukemia, 1001, 1447
high-dose, combined with cisplatin, clinical evaluation of, in recurrent cervical carcinoma, 1023
high-dose, combined with cisplatin, phase I study of, in patients with advanced malignancy, 897
high-dose, severe central nervous system toxicity from: expressive aphasia occurring after the second day of treatment, 313
high-dose, for the treatment of blastic-phase chronic myelogenous leukemia, 881
nucleotide accumulation in human leukemia cells, deoxyguanosine enhancement of, 851
^{3}H-Cytarabine, and monoclonal antibody against bromodeoxyuridine, double labeling of human leukemic cells with, 195

D

Dacarbazine
combined with doxorubicin, in the treatment of childhood

rhabdomyosarcoma, 999
combined with doxorubicin, vincristine, and cyclophosphamide, in the treatment of advanced gastrointestinal leiomyosarcoma, 443
single-dose, combined with dactinomycin, in advanced malignant melanoma, 39
Dactinomycin, combined with single-dose dacarbazine, in advanced malignant melanoma, 39
Daunorubicin
acute nonlymphocytic leukemia induction chemotherapy with, effectiveness in acute lymphocytic leukemia, 1439
promotion of uptake and toxicity by the calcium antagonist tiapamil and its analogs, 673
DC (doxorubicin and lomustine), compared to CF (cyclophosphamide and 5-FU), in randomized trial in hormone-resistant metastatic prostate carcinoma, 105
10-Deaza-aminopterin, compared to the 10-ethyl analog and methotrexate, against some human tumor xenografts in nude mice, 551
Delta-9-tetrahydrocannabinol, compared to levonantradol, antiemetic efficacy of, for chemotherapy-induced nausea and vomiting, 109
4-Demethoxydaunorubicin
phase II study of, in advanced ovarian carcinoma, 559
phase II trial of, in patients with advanced malignant melanoma, 915
4′-Deoxydoxorubicin
phase II trial of, in advanced non-small lung cancer, 1337
phase II trial of, in patients with advanced breast cancer, 1319
1-(2′-Deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5-methyluracil (FMAU), phase I trial of, 55
Deoxyguanosine, enhancement of cytarabine nucleotide accumulation in human leukemia cells, 851
β-2′-Deoxythioguanosine
phase I evaluation of, in pediatric patients with leukemia, 699
phase II trial of, as single agent against advanced measurable tumors of the pancreas, 713
Dexamethasone
combined with diphenhydramine plus metoclopramide, compared to lorazepam, metoclopramide, and dexamethasone, 1257
combined with iv high-dose metoclopramide and diphenhydramine, as antiemetic regimen in cisplatin-based chemotherapy, 909
combined with lorazepam and metoclopramide, improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone, 1257
1,2-Diaminocyclohexane-(4-carboxyphthalato)platinum(II), phase II trial of, in patients with refractory germ cell tumors, 459
Dianhydrogalactitol
phase II trial of, as single agent against advanced measurable tumors of the pancreas, 713
phase II trial of, in the treatment of children with refractory childhood malignancies: a report from the Childrens Cancer Study Group, 1331
Diaziquone
pharmacokinetics of, after three different dosage regimens, 1383
phase I clinical evaluation of, in childhood cancer, 323
phase II clinical trial of, in bronchogenic carcinoma, 921
phase II study of, in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study, 1035
phase II study of, in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group study, 451
phase II study of, in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study, 1033
phase II trial of, in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group study, 709
phase II trial of, in advanced ovarian carcinoma, 339
phase II trial of, in advanced upper aerodigestive cancer, 141
phase II trial of, in patients with colon cancer, 215
for resistant multiple myeloma, 331
Dichloromethotrexate, combined with cisplatin, sequence-dependent synergism in a human colon carcinoma cell line, 279
α-Difluoromethylornithine (DFMO), enhancement of the antiproliferative activity of human interferon by, 97
1,25-Dihydroxyvitamin D_3, in vivo and in vitro effects on human preleukemic and leukemic cells, 1399
Dimethyl sulfoxide (DMSO), inability of, to increase brain uptake of water-soluble compounds: implications to chemotherapy for brain tumors, 305
Diphenhydramine
combined with iv high-dose metoclopramide and dexamethasone, as antiemetic regimen in cisplatin-based chemotherapy, 909
combined with metoclopramide and dexamethasone, compared to lorazepam, metoclopramide, and dexamethasone, 1257
Dipyridamole, modulation of the activity of PALA by, 425
Double labeling of human leukemic cells using ^{3}H-cytarabine and monoclonal antibody against bromodeoxyuridine, 195
Doxorubicin
acute effects of, on chronotropic and inotropic mechanisms in guinea pig atria, 859
cardiotoxicity provoked in relation to second-look laparotomy, acute cardiac failure from, 730
combined with cisplatin, treatment of advanced endometrial carcinoma with: effects on both untreated and previously treated patients, 539
combined with cisplatin and cyclophosphamide (CAP), chemotherapy for advanced endometrial carcinoma, 465
combined with cisplatin and cyclophosphamide (CAP), compared to amsacrine, phase II trial of, in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study, 189
combined with cisplatin and cyclophosphamide (CAP), followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer, 587
combined with cisplatin and cyclophosphamide (CAP), supporting evidence for an active treatment program for advanced salivary gland carcinomas, 319
combined with cyclophosphamide and cisplatin (CISCA), intravenous and intra-arterial, in the management of select patients with urothelial tumors, 33
combined with cyclophosphamide and vincristine (CAV), alternated with etoposide, hexamethylmelamine, and methotrexate (VHM), in small cell carcinoma of the lung, 161
combined with cyclophosphamide and vincristine, alternated with mitomycin, methotrexate, and etoposide, for small cell carcinoma of the lung, 1241

combined with cyclophosphamide and vincristine, failure of scalp hypothermia to prevent hair loss from, 373
combined with dacarbazine, in the treatment of childhood rhabdomyosarcoma, 999
combined with dacarbazine, vincristine, and cyclophosphamide, in the treatment of advanced gastrointestinal leiomyosarcoma, 443
combined with hexamethylmelamine, cisplatin, cyclophosphamide, methotrexate, and 5-FU (CHAMP-5), for ovarian carcinoma: alternating sequences of combination regimens, 689
combined with hexamethylmelamine, cyclophosphamide, and cisplatin, compared to cyclophosphamide plus cisplatin, as initial chemotherapy for stage III and IV ovarian carcinomas, 1243
combined with α-difluoromethylornithine (DFMO), enhancement of the antiproliferative activity of human interferon by, 97
combined with interferon, in renal cell carcinoma, 721
combined with lomustine (DC), compared to cyclophosphamide and 5-FU (CF), in randomized trial in hormone-resistant metastatic prostate carcinoma, 105
combined with methotrexate, 5-FU, and folinic acid, chemotherapy in advanced gastric cancer, 927
combined with mitolactol and tamoxifen, compared to mitomycin and tamoxifen, in patients with previously treated breast cancer, 755
combined with vindesine, adenocarcinoma of unknown primary origin: treatment with, 591
compared to cyclophosphamide, randomized trial of, in diffuse malignant pleural mesothelioma, 1431
compared to epirubicin, pharmacokinetics and metabolism of, in patients with metastatic breast cancer, 633
dynamic left ventricular outflow obstruction and myocardial infarction following administration in a woman affected by unsuspected hypertrophic cardiomyopathy, 241
excretion into human milk, 1387
potentiation and protection of cytotoxicity by cellular glutathione modulation, 1293
skeletal muscle biopsies in patients treated with, 1342
skin toxicity in the mouse, cold protection and heat enhancement of, 431
Drug precipitation within iv tubing, a potential hazard of chemotherapy administration, 1325
Drug resistance
cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs, 515
increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards, 677
phase I study of vinblastine and verapamil given by concurrent iv infusion, 795
promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs, 673

E

Echinomycin, phase I study of, administered on an intermittent bolus schedule, 1365
Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials, 1107
Elliptinium
phase II study of, in advanced breast cancer, 707
phase II trial of, in advanced renal cell carcinoma, 901
Endometrial cancer *see* Cancer, endometrial
Enzyme-inhibition assays, and high-performance liquid chromatographic assays of methotrexate concentrations in serum from patients receiving high-dose therapy: tight binding of some methotrexate to a protein that could be dihydrofolate reductase, 825
4′-Epi-doxorubicin
phase II trial of, in advanced carcinoma of head and neck origin, 125
phase II trial of, in advanced colorectal carcinoma: a Northern California Oncology Group study, 143
Epirubicin
compared to doxorubicin, pharmacokinetics and metabolism of, in patients with metastatic breast cancer, 633
phase II trial of, in gastric cancer, 1275
Esophageal cancer *see* Cancer, esophageal
10-Ethyl, 10-deaza-aminopterin, compared to the parent compound and methotrexate, against some human tumor xenografts in nude mice, 551
Etoposide
bioavailability, pharmacokinetics, and clinical effects of an oral preparation of, 269
circadian rhythm in tolerance of mice for, 1443
combined with 5-azacitidine administered by continuous infusion, therapy for chronic myelogenous leukemia in blast crisis with: a Cancer and Leukemia Group B study, 1027
combined with carmustine, bleomycin, and methotrexate with leucovorin rescue, as re-treatment for unfavorable non-Hodgkin's lymphoma, 783
combined with cisplatin, chemotherapy for refractory small cell carcinoma of the lung, 479
combined with cisplatin, salvage chemotherapy for small cell lung cancer, 369
combined with cisplatin, with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma, 483
combined with cyclophosphamide, effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse, 887
combined with cyclophosphamide and methotrexate, intensive induction treatment of small cell bronchogenic carcinoma with, 1007
combined with hexamethylmelamine and methotrexate (VHM), alternated with cyclophosphamide, doxorubicin, and vincristine (CAV), in small cell carcinoma of the lung, 161
combined with hydroxyurea and ifosfamide (HIB), treatment of relapsed non-Hodgkin's lymphoma with, 225
combined with mitomycin and methotrexate, alternated with cyclophosphamide, doxorubicin, and vincristine, for small cell carcinoma of the lung, 1241
combined with very high-dose cisplatin, salvage therapy for patients with advanced germ cell neoplasms, 259
combined with vincristine and high-dose cisplatin, phase II trial of, in advanced non-small cell lung cancer, 1335
high-dose, in the treatment of relapsed primary brain tumors, 603
in the treatment of multifocal eosinophilic granuloma, 238
multicenter phase II trial of, in refractory small cell lung can-

cer, 127
pharmacokinetic evaluation of increasing dosages of, in a chronic hemodialysis patient, 1279
pharmacokinetics of, in gestochoriocarcinoma, 69
probable cure of small cell carcinoma of the lung by, 235

F

Factorial designs for randomized clinical trials, 1055
5-Fluorodeoxyuridine, cytotoxicity for human colon adenocarcinoma cells compared to normal fetal intestinal cells, 845
Folinic acid, combined with methotrexate, 5-FU, and doxorubicin, as chemotherapy in advanced gastric cancer, 927
FOMi (5-FU, vincristine, and mitomycin), phase II trial of, in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group study, 1313
Food and Drug Administration requirements for approval of new anticancer drugs, 1155
Forphenicinol, combined with cyclophosphamide, effect of, on growth of and immunity to syngeneic murine tumors, 285
5-FU
altered plasma kinetics of, at high dosage in rat and man, 133
cellular basis for the inefficacy of, in human colon carcinoma, 1391
combined with cisplatin, phase I–II trial of, in recurrent head and neck cancer: an effective outpatient schedule, 961
combined with cisplatin, for the treatment of adenocarcinoma of the colon, 1359
combined with cisplatin, treatment of metastatic colorectal carcinoma with, 123
combined with cisplatin and simultaneous radiation therapy, improved control in advanced head and neck cancer with, 933
combined with cyclophosphamide (CF), compared with doxorubicin and lomustine (DC), randomized trial of, in hormone-resistant metastatic prostate carcinoma, 105
combined with cyclophosphamide and methotrexate, tastes associated with parenteral chemotherapy for breast cancer, 1249
combined with cyclophosphamide and prednisone, randomized clinical trial of, with or without tamoxifen, in postmenopausal women with advanced breast cancer, 355
combined with hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, and methotrexate (CHAMP-5), for ovarian carcinoma: alternating sequences of combination regimens, 689
combined with hydroxyurea, factors modifying cytotoxicity induced by, 993
combined with methotrexate, folinic acid, and doxorubicin, as chemotherapy in advanced gastric cancer, 927
combined with mitomycin, adjuvant intrahepatic chemotherapy with, combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study, 129
combined with PALA, a therapeutically inactive biochemical modulating agent, in clinical trials of cancer chemotherapy, 421
combined with sequential intermediate-dose methotrexate, acute renal failure and death following: a possible adverse effect due to concomitant indomethacin administration, 342
combined with sequential methotrexate plus leucovorin rescue, alternated with cisplatin and bleomycin, in patients with head and neck cancer, 1015
combined with thymidine and PALA, phase I–II clinical trial of, 611
combined with vincristine and mitomycin (FOMi), phase II trial of, in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group study, 1313
combined with weekly iv thymidine, phase I evaluation and pharmacokinetic study of, in patients with advanced colorectal carcinoma, 179
cytotoxicity for human colon adenocarcinoma cells compared to normal fetal intestinal cells, 845
infusion in advanced colorectal cancer: a comparison of three dose schedules, 739
infusion, combined with cisplatin bolus, for non-small cell lung cancer, 1253
long-term, ambulatory, continuous iv infusion of, for the treatment of advanced adenocarcinomas, 13
relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug, 645

G

Gallium nitrate
administered by prolonged infusion, metabolic effects of, 653
phase II trial of, in patients with advanced malignant melanoma, 1019
Gastric cancer *see* Cancer, gastric
Gastrointestinal tract cancer *see* Cancer, gastrointestinal tract
Germ cell cancer *see* Cancer, germ cell
Gestochoriocarcinoma *see* Cancer, gestochoriocarcinoma
Glioblastoma *see* Cancer, brain
Glucocorticoid receptor content, of leiomyosarcoma, increased, 907
Glutathione, intracellular, potentiation and protection of doxorubicin cytotoxicity by modulation of, 1293
Glutathione-*S*-transferase activity, increased, in a cell line with acquired resistance to nitrogen mustards, 677

H

Head and neck cancer *see* Cancer, head and neck
Hexamethylmelamine
combined with cyclophosphamide, doxorubicin, and cisplatin, compared to cyclophosphamide plus cisplatin, as initial chemotherapy for stage III and IV ovarian carcinomas, 1243
combined with doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU (CHAMP-5), for ovarian carcinoma: alternating sequences of combination regimens, 689
combined with etoposide and methotrexate (VHM), alternated with cyclophosphamide, doxorubicin, and vincristine (CAV), in small cell carcinoma of the lung, 161
combined with teniposide, cisplatin, and prednisolone, treatment of refractory Hodgkin's disease with: Cancer and Leukemia Group B trial 8171, 719
pharmacokinetics of, administered via the ip route in an oil

emulsion vehicle, 657
phase II trial of, as single agent against advanced measurable tumors of the pancreas, 713
High-performance liquid chromatographic and enzyme-inhibition assays, of methotrexate concentrations in serum from patients receiving high-dose therapy: tight binding of some methotrexate to a protein that could be dihydrofolate reductase, 825
HIV (hydroxyurea, ifosfamide, and etoposide), treatment of relapsed non-Hodgkin's lymphoma with, 225
Hodgkin's disease *see* Cancer, Hodgkin's disease
Hydroxyurea
combined with 5-FU, factors modifying cytotoxicity induced by, 993
combined with ifosfamide and etoposide (HIV), treatment of relapsed non-Hodgkin's lymphoma with, 225
5-Hydroxyuridine, selective cytotoxicity of, for human colon adenocarcinoma cells, 845
Hyperalimentation, adjuvant central iv, effect of, on the survival and response to treatment of patients with small cell lung cancer: a randomized trial, 167
Hypercalcemia, treatment of, with gallium nitrate administered by prolonged infusion, 653
Hypothermia, scalp, failure to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine, 373

I

Ifosfamide
combined with hydroxyurea and etoposide (HIB), treatment of relapsed non-Hodgkin's lymphoma with, 225
combined with mesna, phase II trial of, in previously treated metastatic sarcoma, 499
high-dose, in advanced osteosarcoma, 115
Immunotherapy
combined-modality treatment of inoperable lung cancer (iv immunotherapy, chemotherapy, and radiotherapy), 251
cooperative trial of immunotherapy for nasopharyngeal carcinoma with transfer factor from donors with Epstein-Barr virus antibody activity, 761
evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy, 663
In vitro studies *see also* Cell culture studies
acute effects of doxorubicin on chronotropic and inotropic mechanisms in guinea pig atria, 859
time dependency in plasmatic protein binding of cisplatin, 79
Indomethacin
and antiproliferative activity of human interferon, 97
as possible cause of acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU, 342
Inosine, combined with thymidine, as "early" protection against methotrexate toxicity, 867
Intensive induction chemotherapy, for small cell anaplastic carcinoma of the lung, 571
Interferon
combined with doxorubicin, in renal cell carcinoma, 721
rDNA human alpha-2, phase II study of, in multiple myeloma, 495
high-dose recombinant leukocyte alpha-2, phase II trial of, for metastatic colorectal cancer without previous systemic treatment, 185
human, enhancement of the antiproliferative activity of, by polyamine depletion, 97
human alpha lymphoblastoid (Wellferon), coagulopathy induced by continuous infusion of high doses of, 315
human alpha lymphoblastoid (Wellferon), phase II study of, in patients with advanced renal carcinoma, 817
human alpha lymphoblastoid (Wellferon), phase II trial of, given weekly as treatment of advanced breast cancer, 547
α(human leukocyte), combined with vinblastine, treatment of renal cell carcinoma with: a phase I–II trial, 263
lymphoblastoid, phase II trial of, in metastatic malignant melanoma, 813
lymphoblastoid, prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for, 743
recombinant alpha, phase II study of, in the treatment of advanced non-small cell lung carcinoma, 1031
recombinant alpha-2, in the treatment of hairy cell leukemia, 791
recombinant human leukocyte A, treatment of multiple myeloma with, 1433
recombinant leukocyte alpha, in advanced ovarian carcinoma, 895
Interim analysis and interim reporting of results in cancer clinical trials, 1101
Iron metabolism, effects of cytotoxic agents on, 729
Iv tubing, drug precipitation within: a potential hazard of chemotherapy administration, 1325

J

JM9, activity of, in advanced ovarian cancer: a phase I–II trial, 409

L

Large bowel cancer *see* Cancer, large bowel
Leucovorin rescue
methotrexate with, combined with etoposide, carmustine, and bleomycin, as re-treatment for unfavorable non-Hodgkin's lymphoma, 783
sequential methotrexate-5-FU with, alternated with cisplatin and bleomycin, in patients with head and neck cancer, 1015
Leukemia
acute
amsacrine with high-dose cytarabine in, 1447
clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with: a Leukemia Intergroup report, 240
lymphoblastic, in adults, long-term relapse-free survival in, 153
lymphoblastic, in children, prognostic implications of blast cell morphology in: a report from the Childrens Cancer Study Group, 1211
lymphocytic, effectiveness of acute nonlymphocytic leukemia induction chemotherapy in, 1439

monoblastic, brachial plexus neuropathy following high-dose cytarabine in, 1005
myelogenous, intensive short-term chemotherapy for patients with: long term follow-up, 1425
myelogenous, mathematical model of remission duration in, 595
nonlymphatic, hyperphosphatemic renal failure following treatment of, 563
nonlymphoblastic, phase I study of bisantrene in, 703
nonlymphocytic, estimate of overall treatment results in, based on age-specific rates of incidence and of complete remission, 5
nonlymphocytic, human acute, use of protein A-sepharose-treated sera in: lack of toxicity, 1449
nonlymphocytic, induction chemotherapy, effectiveness of in acute lymphocytic leukemia, 1439
nonlymphocytic, in relapse, cyclophosphamide/etoposide: effective reinduction therapy for children with, 887
phase I evaluation of β-2′-deoxythioguanosine in pediatric patients with, 699
phase I–II trial of mitoxantrone in, 61
refractory, amsacrine in, 787
refractory adult, sequentially administered 5-azacitidine and amsacrine in: a phase I–II trial of the Southeastern Cancer Study Group, 807
treatment with amsacrine and high-dose cytarabine, 1001
allergic rections to teniposide in patients with, 439
autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of: first clinical observations, 953
chronic
B-cell lymphocytic, leukemic meningitis in, 687
myelogenous, in blast crisis, therapy for, with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia Group B study, 1027
myelogenous, in blast crisis, treatment of, with chemotherapy incorporating vindesine-prednisolone, 1297
myelogenous, in blast crisis, treatment of, with vincristine, prednisone, and cytarabine, 923
myelogenous, blastic phase, high-dose cytarabine for the treatment of, 881
myeloid, blast crisis of, treatment of, with vindesine and prednisone, 203, 445
difficulty of interpreting disease-free interval curves when substantial numbers of patients die in remission, 924
1,25-dihydroxyvitamin D_3: in vivo and in vitro effects on human preleukemic and leukemic cells, 1399
hairy cell, recombinant alpha-2 interferon in the treatment of, 791
human cells, deoxyguanosine enhancement of cytarabine nucleotide accumulation in, 851
human cells, double labeling of, using ^{3}H-cytarabine and monoclonal antibody against bromodeoxyuridine, 195
myeloblastic, coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon, 315
myelodysplastic disorders, phase I–II study of 13-*cis*-retinoic acid in, 1369
ocular, treatment of, with local chemotherapy, 119
L1210 leukemia *see* Tumor systems, animals
Levonantradol, compared to delta-9-tetrahydrocannabinol, antiemetic efficacy of, for chemotherapy-induced nausea and vomiting, 100
Lomustine
combined with cimetidine, in the treatment of a patient with malignant glioblastoma: a case report, 733
combined with doxorubicin (DC), compared to cyclophosphamide and 5-FU (CF), randomized trial of, in hormone-resistant metastatic prostate carcinoma, 105
combined with vincristine and procarbazine, in the treatment of metastatic malignant melanoma, 941
combined with vindesine, cisplatin, and cyclophosphamide (VCPC), and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung, 469
Eastern Cooperative Oncology Group phase II study of, in advanced measurable colorectal cancer, 543
enhancement of antitumor efficacy of, by the radiosensitizer RSU 1069, 1409
Lorazepam, combined with metoclopramide and dexamethasone, consecutive dose-finding trials: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone, 1257
Lung cancer *see* Cancer, lung
Lymphoma *see* Cancer, lymphoma

M

M-component changes, rate of, and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio, 971
Mannitol, immediate hypersensitivity to: a potential cause of apparent hypersensitivity to cisplatin, 562
Mathematical model of remission duration in acute myelogenous leukemia, 595
Mathematical modeling, role of, in protocol formulation in cancer chemotherapy, 1041
Maytansine, phase II trial of, as single agent against advanced measurable adenocarcinoma of the pancreas, 417
Measurement error, influence of, on response rates, 1127
Medroxyprogesterone acetate
endocrine effects of: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer, 977
influence of aminoglutethimide on plasma levels of: its correlation with serum cortisol, 85
Melanoma *see* Cancer, melanoma
Melphalan
intensive, and autologous bone marrow transplantation, treatment of metastatic malignant melanoma with, 473
phase II evaluation of, in adenocarcinoma of the pancreas, 917
a potential new agent in the treatment of childhood rhabdomyosarcoma, 91
Meningitis, leukemic, in B-cell chronic lymphocytic leukemia, 687
6 Mercaptopurine, treatment of small cell lung cancer with: a phase II study, 555
Mesna
combined with high-dose ifosfamide, in advanced osteosarcoma, 115
combined with ifosfamide, phase II trial of, in previously treated metastatic sarcoma, 499
Mesothelioma *see* Cancer, mesothelioma
Methodologic guidelines for reports of clinical trials, 1

Methodology and quality assurance in cancer clinical trials, symposium on, 1039
Methotrexate
analysis of "early" thymidine/inosine protection as an adjunct to, 867
bioavailability and pharmacokinetics, 833
combined with cyclophosphamide and etoposide, intensive induction treatment of small cell bronchogenic carcinoma with, 1007
combined with cyclophosphamide and 5-FU, tastes associated with parenteral chemotherapy for breast cancer, 1249
combined with etoposide and hexamethylmelamine (VHM), alternated with cyclophosphamide, doxorubicin, and vincristine (CAV), in small cell carcinoma of the lung, 161
combined with 5-FU, folinic acid, and doxorubicin, chemotherapy in advanced gastric cancer, 927
combined with hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide and 5-FU (CHAMP-5), for ovarian carcinoma: alternating sequences of combination regimens, 689
combined with mitoguazone, bleomycin, and cisplatin, chemotherapy for esophageal cancer with, 21
combined with mitomycin, negative experience in untreated colorectal carcinoma, 223
combined with mitomycin and etoposide, alternated with cyclophosphamide, doxorubicin, and vincristine, for small cell carcinoma of the lung, 1241
compared to cisplatin, for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study, 577
compared to 10-deaza-aminopterin and the 10-ethyl analog, against some human tumor xenografts in nude mice, 551
high-dose, high-performance liquid chromatographic and enzyme-inhibition assays of methotrexate concentrations in serum from patients receiving: tight binding of some methotrexate to a protein that could be dihydrofolate reductase, 825
with leucovorin rescue, combined with etoposide, carmustine, and bleomycin, as re-treatment for unfavorable non-Hodgkin's lymphoma, 783
sequential, combined with 5-FU plus leucovorin rescue, alternated with cisplatin and bleomycin, in patients with head and neck cancer, 1015
sequential intermediate-dose, combined with 5-FU, acute renal failure and death following: a possible adverse effect due to concomitant indomethacin administration, 342
***N*-Methylformamide**
-induced hypophosphatemia, 343
phase I study of, in patients with advanced cancer, 489
Methylprednisone, oral, action of, in terminal cancer patients: a prospective randomized double-blind study, 751
Metoclopramide
antiemetic activity of two different high doses of, in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research, 1353
combined with diphenhydramine plus dexamethasone, compared to lorazepam, metoclopramide, and dexamethasone, 1257
combined with lorazepam and dexamethasone, improved subjective effectiveness over the combination of diphenydramine plus metoclopramide plus dexamethasone, 1257
compared to alizapride, for efficacy against cisplatin-induced emesis, 1301
iv high-dose, combined with dexamethasone and diphenhydramine, as antiemetic regimen in cisplatin-based chemotherapy, 909
iv high-dose, used as an antiemetic agent during cancer chemotherapy, parkinsonism following, 341
in vincristine-induced ileus, 1309
Mitoguazone
combined with methotrexate, bleomycin, and cisplatin, chemotherapy for esophageal cancer with, 21
hypoglycemia: not an important side effect of, 1340
phase II trial of, in malignant primary brain tumors, 329
phase II trial of, in patients with refractory germ cell tumors, 461
Mitolactol
combined with doxorubicin and tamoxifen, compared to mitomycin and tamoxifen, in patients with previously treated breast cancer, 755
phase II study of, in advanced malignant melanoma, 723
phase II study of, in metastatic malignant melanoma, 65
Mitomycin
combined with bleomycin and cisplatin, for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group, 903
combined with 5-FU, adjuvant intrahepatic chemotherapy with, combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study, 129
combined with 5-FU and vincristine (FOMi), phase II trial of, in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group study, 1313
combined with methotrexate, negative experience in untreated colorectal carcinoma, 223
combined with methotrexate and etoposide, alternated with cyclophosphamide, doxorubicin, and vincristine, for small cell carcinoma of the lung, 1241
combined with tamoxifen, compared to mitolactol, doxorubicin, and tamoxifen, in patients with previously treated breast cancer, 755
combined with vinblastine, treatment of non-small cell bronchogenic carcinoma with: a Southwest Oncology Group study, 583
combined with vindesine, compared to vindesine plus cisplatin, in the treatment of advanced non-small cell lung cancer, 945
excessive tissue ulceration due to apparent sensitivity reactions to, 925
-induced syndrome of thrombotic thrombocytopenic purpura, effect of cyclophosphamide on, 565
low-dose, phase II study of, in patients with ovarian cancer previously treated with chemotherapy, 1271
Mitoxantrone
in adenocarcinoma of the endometrium: a Southwest Oncology Group study, 1329
phase I trial of, in children, 403
phase II study of, in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study, 1033
phase II trial of, in advanced sarcomas: a Southwest Oncology Group study, 231
phase II trial of, in multiple myeloma: a Southwest Oncology Group study, 1321
phase II trial of, in refractory germ cell tumors: a trial of the

Southeastern Cancer Study Group, 1455
phase I–II trial of, in acute leukemia, 61
Mitozolomide, phase I clinical trial of, 801
Monoclonal antibody
against bromodeoxyuridine, and ^{3}H-cytarabine, double labeling of human leukemic cells with, 195
to a Lewis lung carcinoma-associated antigen: different effects on primary tumor and its metastases, 985
Multifocal eosinophilic granuloma, etoposide in the treatment of, 238
Multiple regression models for prognostic prediction; advantages, problems, and suggested solutions, 1071
Myeloma *see* Cancer, myeloma

N

Nasopharyngeal cancer *see* Cancer, nasopharyngeal
Neuroblastoma *see* Cancer, neuroblastoma
Nitrogen mustards, increased glutathione-*S*-transferase activity in a cell line with acquired resistance to, 677

O

Ovarian cancer *see* Cancer, ovarian

P

PALA
combined with 5-FU, as a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy, 421
combined with thymidine and 5-FU, phase I–II clinical trial of, 611
modulation of the activity of, by dipyridamole, 425
Pancreatic cancer *see* Cancer, pancreatic
Pathology quality control in the cooperative clinical cancer trial programs, 1207
Peptichemio
in pretreated patients with ovarian cancer, 17
role of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with, 971
Pharmaceutical industry, clinical quality assurance in the, 1195
Pharmacokinetics
altered plasma kinetics of 5-FU at high dosage in rat and man, 133
arterial drug infusion with extracorporeal removal: internal carotid carmustine in the rhesus monkey, 293
bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide, 269
clinical, of vindesine infusion, 839
comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer, 633
competitive protein-binding assay for trimetrexate, 641
deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells, 851
of diaziquone after three different dosage regimens, 1383
doxorubicin and cisplatin excretion into human milk, 1387
effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex, 875
of etoposide in gestochoriocarcinoma, 69
evaluation of increasing dosages of etoposide in a chronic hemodialysis patient, 1279
of hexamethylmelamine administered via the ip route in an oil emulsion vehicle, 657
high-performance liquid chromatographic and enzyme-inhibition assays of methotrexate concentrations in serum from patients receiving high-dose therapy: tight binding of some methotrexate to a protein that could be dihydrofolate reductase, 825
inability of dimethyl sulfoxide to increase brain uptake of water-soluble compounds: implications to chemotherapy for brain tumors, 305
influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol, 85
of methotrexate, 833
phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma, 179
promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs, 673
relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug, 645
single-dose study of 13-*cis*-retinoic acid in man, 275
of teniposide in patients with ovarian cancer, 73
time dependency in plasmatic protein binding of cisplatin, 79
ultrafiltrate and total platinum in plasma and cerebrospinal fluid in a patient with neuroblastoma, 1441
Phase I studies
of biological response modifiers, applicability of results in the design of phase II and III trials, 1171
of bisantrene in acute nonlymphoblastic leukemia, 703
of 1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5-methyluracil (FMAU), 55
of β-2′-deoxythioguanosine in pediatric patients with leukemia, 699
of diaziquone in childhood cancer, 323
of divided-dose vinblastine in advanced malignancy, 607
of echinomycin administered on an intermittent bolus schedule, 1365
of high-dose cytarabine and cisplatin in patients with advanced malignancy, 897
of *N*-methylformamide in patients with advanced cancer, 489
of mitoxantrone in children, 403
of mitozolomide, 801
of tolerance to antineoplastic agents in children and adults, 1263
of vinblastine and verapamil given by concurrent iv infusion, 795
of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma, 179
Phase II studies
of aclarubicin in advanced breast cancer (Southeastern Cancer Study Group), 1029
of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581) (Eastern Cooperative Oncology Group), 451
of aclarubicin in patients with lymphoma, 1315
of aclarubicin in previously untreated patients with advanced soft tissue sarcoma (Southeastern Cancer Study Group), 725
of adjuvant intrahepatic chemotherapy with mitomycin and 5-

FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon (Southwest Oncology Group), 129
of amsacrine in children with solid tumors (Pediatric Oncology Group), 335
of amsacrine in gastric carcinoma (Southwest Oncology Group), 557
of amsacrine in small cell lung cancer (Southeastern Cancer Study Group), 333
of amsacrines (*m*-AMSA and *m*-AMSA lactate) in refractory lymphomas, 965
of biological response modifiers, applicability of phase I trial results in the design of, 1171
of bisantrene in metastatic breast cancer, 337
of bisantrene in patients with advanced non-small cell lung carcinoma, 209
of bisantrene in patients with advanced renal cell carcinoma, 727
of bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix (Northern California Oncology Group), 903
of carboplatin in advanced breast carcinoma (Cancer and Leukemia Group B), 919
of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract, 1453
of cisplatin in advanced osteogenic sarcoma, 211
of cisplatin in children with recurrent brain tumors, 911
of cisplatin in squamous carcinoma of the esophagus (Southeastern Cancer Study Group), 1457
of cisplatin in the treatment of advanced gastric carcinoma, 449
of cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma (Southeastern Cancer Study Group), 821
of combined chemotherapy (vindesine, lomustine, cisplatin, and cyclophosphamide) and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung, 469
of continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary, 139
of continuous-infusion vindesine in refractory carcinoma of the cervix, 1317
of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder (Southwest Oncology Group), 189
of 4-demethoxydaunorubicin in advanced ovarian carcinoma, 559
of 4-demethoxydaunorubicin in patients with advanced malignant melanoma, 915
of 4′-deoxydoxorubicin in advanced non-small cell lung cancer, 1337
of 4′-deoxydoxorubicin in patients with advanced breast cancer, 1319
of 1,2-diaminocyclohexane-(4-carboxyphthalato)platinum(II) in patients with refractory germ cell tumors, 459
of dianhydrogalactitol in the treatment of children with refractory childhood malignancies (Childrens Cancer Study Group), 1331
of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients (Southwest Oncology Group), 709
of diaziquone in advanced ovarian carcinoma, 339
of diaziquone in advanced soft tissue and bony sarcoma (Southwest Oncology Group), 1035
of diaziquone in advanced upper aerodigestive cancer, 141
of diaziquone in bronchogenic carcinoma, 921
of diaziquone in patients with colon cancer, 215
of rDNA human alpha-2 interferon in multiple myeloma, 495
of elliptinium in advanced breast cancer, 707
of elliptinium in advanced renal cell carcinoma, 901
of 4′-epi-doxorubicin in advanced carcinoma of head and neck origin, 125
of 4′-epi-doxorubicin in advanced colorectal carcinoma (Northern California Oncology Group), 143
of epirubicin in gastric cancer, 1275
of etoposide in refractory small cell lung cancer, 127
of etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma, 483
of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer, 1335
of 5-day infusion of vinblastine in patients with advanced ovarian carcinoma, 229
of 5-FU, vincristine, and mitomycin (FOMi) in metastatic bronchioloalveolar cell lung cancer (Southwest Oncology Group), 1313
of gallium nitrate in patients with advanced malignant melanoma, 1019
of hexamethylmelamine, dianhydrogalactitol, razoxane, and β-2′-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas, 713
of high-dose cisplatin in patients with malignant mesothelioma, 711
of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment, 185
of human lymphoblastoid interferon in patients with advanced renal carcinoma, 817
of ifosfamide with mesna in previously treated metastatic sarcoma, 499
of low-dose mitomycin in patients with ovarian cancer previously treated with chemotherapy, 1271
of α-lymphoblastoid interferon given weekly as treatment of advanced breast cancer, 547
of lymphoblastoid interferon in metastatic malignant melanoma, 813
of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas, 417
of melphalan in adenocarcinoma of the pancreas, 917
of 6-mercaptopurine in the treatment of small cell lung cancer, 555
of mitoguazone in malignant primary brain tumors, 329
of mitoguazone in patients with refractory germ cell tumors, 461
of mitolactol in advanced malignant melanoma, 723
of mitolactol in metastatic malignant melanoma, 65
of mitomycin in disseminated malignant melanoma, 1451
of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma (Eastern Cooperative Oncology Group), 1033
of mitoxantrone in advanced sarcomas (Southwest Oncology Group), 231
of mitoxantrone in multiple myeloma (Southwest Oncology

Group), 1321
of mitoxantrone in refractory germ cell tumors (Southeastern Cancer Study Group), 1455
randomized clinical trials, 1375
of razoxane, Yoshi-864, piperazinedione, and lomustine in advanced measurable colorectal cancer (Eastern Cooperative Oncology Group), 543
of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma, 1031
of recombinant human leukocyte A interferon in the treatment of multiple myeloma, 1433
of spirogermanium in patients with advanced carcinoma of the cervix, 457
of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma, 137
of vindesine and prednisone in the treatment of chronic myeloid leukemia blast crisis, 445
Phase I–II studies
of cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule, 961
of α(human leukocyte) interferon and vinblastine in the treatment of renal cell carcinoma, 263
of human lymphoblastoid interferon, for children with refractory myelocytic leukemia, 315
of JM9 in advanced ovarian cancer, 409
of mitoxantrone in acute leukemia, 61
of 13-*cis*-retinoic acid in myelodysplastic disorders, 1369
of sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia (Southeastern Cancer Study Group), 807
of thymidine, 5-FU, and PALA given in combination, 611
Phase III studies
of biological response modifiers, applicability of phase I trial results in the design of, 1171
of combination chemotherapies, an efficient design for, 1147
size of, 1087
Physicians, participation in randomized clinical trials, 1095
Piperazinedione, Eastern Cooperative Oncology Group phase II study of, in advanced measurable colorectal cancer, 543
Platinum, ultrafiltrate and total, in plasma and cerebrospinal fluid in a patient with neuroblastoma, 1441
Poly ICLC, liver enzyme abnormalities after infusions of, 1342
Prednisolone, combined with vindesine and additional cytarabine, treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating, 1297
Prednisone
combined with cyclophosphamide and 5-FU, randomized clinical trial of, with or without tamoxifen, in postmenopausal women with advanced breast cancer, 355
combined with vincristine and cytarabine, treatment of blast crisis of chronic myelogenous leukemia with, 923
combined with vindesine, in the treatment of blast crisis of chronic myeloid leukemia, 203, 445
Procarbazine, combined with lomustine and vincristine, in the treatment of metastatic malignant melanoma, 941
Prognostic prediction, multiple regression models for: advantages, problems, and suggested solutions, 1071
Prostatic cancer *see* Cancer, prostatic
Protein A-sepharose-treated sera, in human acute nonlymphocytic leukemia: lack of toxicity, 1449
Quality assurance in cancer clinical trials
in a cooperative group, 1189
panel discussion, 1223
pathology quality control in the cooperative clinical cancer trial programs, 1207
in the pharmaceutical industry, 1195
prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group, 1211
of radiotherapy, 1199
site visit monitoring program of the clinical cooperative groups: results of the first 3 years, 1177
Quality of life measurement, risks and benefits, 1115

R

Radiation therapy
alternation with chemotherapy in cancer management: summary of the Division of Cancer Treatment Workshop, 769
combination chemotherapy followed by, in patients with regional stage III unresectable non-small cell lung cancer, 587
combined-modality treatment of inoperable lung cancer (iv immunotherapy, chemotherapy, and radiotherapy), 251
hepatic irradiation, combined with adjuvant intrahepatic chemotherapy with mitomycin and 5-FU, in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study, 129
multiple-fraction daily, alternating with chemotherapy in patients with stage IV non-oat cell lung cancer, 25
prophylactic whole-brain irradiation and combination chemotherapy, disturbing central nervous system complications following, in patients with small cell lung cancer, 1429
quality assurance of, in clinical trials, 1199
radical, and combined chemotherapy (vindesine, lomustine, cisplatin, and cyclophosphamide) in inoperable nonmetastatic squamous cell carcinoma of the lung, 469
and simultaneous cisplatin/5-FU chemotherapy, improved control in advanced head and neck cancer with, 933
Razoxane
Eastern Cooperative Oncology Group phase II study of, in advanced measurable colorectal cancer, 543
phase II trial of, as single agent against advanced measurable tumors of the pancreas, 713
Remission *see also* Survival
difficulty of interpreting disease-free interval curves when substantial numbers of patients die in remission, 924
mathematical model of duration in acute myelogenous leukemia, 595
Renal cancer *see* Cancer, renal
Renal cell cancer *see* Cancer, renal cell
Renal failure, pharmacokinetic evaluation of increasing dosages of etoposide in a patient with, 1279
Response surface methodology, and the design of clinical trials for the evaluation of cancer chemotherapy, 1049
13-*cis*-Retinoic acid
phase I–II study of, in myelodysplastic disorders, 1369
single-dose pharmacokinetic study of, in man, 275
Rhabdomyosarcoma *see* Cancer, sarcoma
RSU 1069, enhancement of antitumor efficacy of lomustine by, 1409

S

Sarcoma *see* Cancer, sarcoma
Semustine, combined with cyclophosphamide and vincristine, intensive induction chemotherapy for small cell anaplastic carcinoma of the lung, 571
Sister chromatid exchanges, induced by cancer chemotherapeutic agents in vitro and in vivo: consideration of the hazard of drugs as possible mutagens and carcinogens causing second malignancies, 505
Site visit monitoring program of the clinical cooperative groups, results of the first 3 years, 1177
Spirogermanium
continuous-infusion, for the treatment of refractory carcinoma of the ovary: a phase II trial, 139
phase II study of, in patients with advanced carcinoma of the cervix, 457
Subrenal capsule assay, feasibility of transporting tissues to a central facility for testing, 717
Survival *see also* Remission
comparison of, by treatment outcome variables in cancer clinical trials, 1139
tree-structured analysis of, 1065
Symposium on methodology and quality assurance in cancer clinical trials, 1039

T

Tamoxifen
combined with cyclophosphamide, 5-FU, and prednisone, randomized clinical trial of, in postmenopausal women with advanced breast cancer, 355
combined with mitolactol and doxorubicin, compared to mitomycin and tamoxifen, in patients with previously treated breast cancer, 755
combined with mitomycin, compared to mitolactol, doxorubicin, and tamoxifen, in patients with previously treated breast cancer, 755
endometrial adenocarcinoma in breast cancer patients receiving, 237
as therapy for colorectal adenocarcinoma: a Southwest Oncology Group study, 113
as therapy in premenopausal women with metastatic breast cancer, 363
Taxol-resistant mutants of Chinese hamster ovary cells, cross-resistance to other anticancer drugs, 515
Tegafur, oral, relevance of the pharmacology of, to its use as a 5-FU pro-drug, 645
Teniposide
allergic reactions to, in patients with neuroblastoma and lymphoid malignancies, 439
combined with cisplatin, hexamethylmelamine, and prednisolone, treatment of refractory Hodgkin's disease with: Cancer and Leukemia Group B trial 8171, 719
pharmacokinetics of, in patients with ovarian cancer, 73
Testicular cancer *see* Cancer, testicular
6-Thioguanine, acute nonlymphocytic leukemia induction chemotherapy, effectiveness in acute lymphocytic leukemia, 1439
Thymidine
combined with 5-FU and PALA, phase I–II clinical trial of, 611
combined with inosine, as "early" protection of methotrexate toxicity, 867
weekly iv, combined with 5-FU, phase I evaluation and pharmacokinetic study of, in patients with advanced colorectal carcinoma, 179
Thymoma *see* Cancer, thymoma
Thymosin fraction 5, phase II study of, in the treatment of metastatic renal cell carcinoma, 137
Tiapamil, promotion of daunorubicin uptake and toxicity by, 673
Transfer factor from donors with Epstein-Barr virus antibody activity, cooperative trial of immunotherapy for nasopharyngeal carcinoma with, 761
Tree-structured survival analysis, 1065
Trilostane, for advanced breast cancer, 351
Trimetrexate, competitive protein-binding assay for, 641
D-Trp-6-LHRH, response of patient with advanced ovarian carcinoma to, 1341
Tumor systems, animals *see also* Xenografts
analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy, 867
antitumor activity of *trans*-bis(salicylaldoximato)copper (II): a novel antiproliferative metal complex, 1021
B16 melanoma, enhancement of tumorigenicity of, in heterogenetic mice by administration of copper chelates, 1283
clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: reply to a commentary, 1339
KHT sarcoma, enhancement of antitumor efficacy of lomustine by the radiosensitizer RSU 1069, 1409
Lewis lung carcinoma, treatment with monoclonal antibody: different effects on primary tumor and its metastases, 985
NMU-1, a new transplantable mouse lung tumor: biological and chemosensitivity properties in vivo, 219
P388 leukemia
cure of mice bearing, by vincristine in combination with a calcium channel blocker, 523
promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs, 673
stability of the in vivo model in evaluation of antitumor activity of natural products, 683
syngeneic murine tumors, effect of forphenicinol in combination with cyclophosphamide on growth of and immunity to, 285
synthesis, toxicity, and therapeutic efficacy of 4-amino-*N*-(2′-aminophenyl)benzamide: a new compound preferentially active in slowly growing tumors, 1415
vitamin K_3 inhibition of malignant murine cell growth and human tumor colony formation, 527
Walker 256 rat mammary carcinoma, increased glutathione-*S*-transferase activity in a cell line with acquired resistance to nitrogen mustards, 677

V

Verapamil
combined with vinblastine, phase I study of, 795
combined with vincristine, cure of mice bearing P388 leukemia by, 523
VHM (etoposide, hexamethylmelamine, and methotrexate), alternated with CAV (cyclophosphamide, doxorubicin, and vincristine), in small cell carcinoma of the lung, 161
Vinblastine
combined with cisplatin, compared with vindesine plus cisplatin, randomized trial in patients with non-small cell lung cancer, with an analysis of methods of response assessment, 387
combined with cisplatin and bleomycin, in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group, 821
combined with α(human leukocyte) interferon, treatment of renal cell carcinoma with: a phase I–II trial, 263
combined with mitomycin, treatment of non-small cell bronchogenic carcinoma with: a Southwest Oncology Group study, 583
combined with verapamil given by concurrent iv infusion, phase I study of, 795
continuous infusion of, for advanced hormone-refractory prostate cancer, 885
divided-dose, phase I study of, in advanced malignancy, 607
5-day infusion, failure of, in the treatment of patients with renal cell carcinoma, 227
5-day infusion, phase II study of, in patients with advanced ovarian carcinoma, 229
-resistant mutants of Chinese hamster ovary cells, cross-resistance of, to other anticancer drugs, 515
Vinca alkaloid, -induced cardiovascular autonomic neuropathy, 149
Vincristine
combined with cyclophosphamide and doxorubicin (CAE), alternated with etoposide, hexamethylmelamine, and methotrexate (VHM), in small cell carcinoma of the lung, 161
combined with cyclophosphamide and doxorubicin, alternated with mitomycin, methotrexate, and etoposide, for small carcinoma of the lung, 1241
combined with cyclophosphamide and doxorubicin, failure of scalp hypothermia to prevent hair loss, 373
combined with cyclophosphamide and semustine, intensive induction chemotherapy for small cell anaplastic carcinoma of the lung, 571
combined with doxorubicin, dacarbazine, and cyclophosphamide, in the treatment of advanced gastrointestinal leiomyosarcoma, 443
combined with etoposide and high-dose cisplatin, phase II trial of, in advanced non-small cell lung cancer, 1335
combined with 5-FU and mitomycin (FOMi), phase II trial of, in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group study, 1313
combined with lomustine and procarbazine, in the treatment of metastatic malignant melanoma, 941
combined with prednisone and cytarabine, treatment of blast crisis of chronic myelogenous leukemia with, 923
cure of mice bearing P388 leukemia by, in combination with a calcium channel blocker, 523
-induced ileus, metoclopramide in, 1309
Vindesine
combined with cisplatin, compared to vinblastine plus cisplatin, randomized trial in patients with non-small cell lung cancer, with an analysis of methods of response assessment, 387
combined with cisplatin, compared to vindesine plus mitomycin, in the treatment of advanced non-small cell lung cancer, 945
combined with doxorubicin, as treatment for adenocarcinoma of unknown primary origin, 591
combined with lomustine, cisplatin, and cyclophosphamide (VCPC), and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung, 469
combined with mitomycin, compared to vindesine plus cisplatin, in the treatment of advanced non-small cell lung cancer, 945
combined with prednisolone and additional cytarabine, treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating, 1297
combined with prednisone, treatment of chronic myeloid leukemia blast crisis with, 203, 445
continuous infusion, in refractory carcinoma of the cervix: a phase II trial, 1317
infusion, clinical pharmacokinetics of, 839
Vitamin B_{12} inactivation, failure to demonstrate in patients treated with cisplatin, 453
Vitamin D metabolite, 1,25-dihydroxyvitamin D_3: in vivo and in vitro effects on human preleukemic and leukemic cells, 1399
Vitamin K_3, inhibition of malignant murine cell growth and human tumor colony formation, 527

W

Warfarin
combined with vitamin K_3, inhibition of malignant murine cell growth and human tumor colony formation by, 527
possible interactions with antineoplastic drugs, 244

X

Xenografts
melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma, 91
new folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice, 551
subrenal capsule assay: feasibility of transporting tissues to a central facility for testing, 717

Y

Yoshi-864, Eastern Cooperative Oncology Group phase II study of, in advanced measurable colorectal cancer, 543

Author Index

A

Aabo K, 449, 730
Abad-Esteve A, 909
Abbas JS, 891
Abe T, 505
Abeloff MD, 161, 451
Abratt RP, 235
Abromowitch M, 439
Ackland SP, 562
Adams LJ, 1437
Adenis L, 79
Adler S, 807
Ahlgren JD, 813, 1365
Ahmann DL, 1451
Ahmed T, 1001
Akman SA, 527, 851
Alberts DS, 431, 833, 1321
Alcock NW, 653
Alexieva-Figusch J, 363
Alfrey CP, Jr, 729
Allegra CJ, 641
Alliet K, 1409
Al-Sarraf M, 189
Amaki I, 1433
Amato D, 587
Amiel JL, 707, 901
Anaissie E, 891
Anderson JR, 719, 1139
Anderson K, 331, 1027
Anderson KC, 1347
Anderson PN, 127
Andrews WG, 1365
Antman KH, 499
Antonow DR, 1437
Apollonj C, 985
Arcangeli G, 25
Arlin ZA, 61, 1001
Armentrout S, 61
Armitage JO, 153
Arnold D, 137
Arrizgada R, 469
Asbury RF, 223
Ascari E, 971
Ash R, 1437
Athens JW, 113
Atkins JN, 897
Atkinson EN, 1023
Aunan SB, 153
Ausman RK, 13
Ayoob M, 813

B

Bach F, 1431
Bachur NR, 851, 1387
Bagin R, 387
Bailleul F, 1443
Bajetta E, 965
Baker J, 43
Baker LH, 127, 583, 709, 1035
Balcerzak SP, 231, 1035, 1321
Baldeyrou P, 469
Balikian J, 587
Ballard WP, 689
Ballatori E, 1353
Ballon SC, 465, 903
Bancillon A, 703
Band P, 275
Barbet J, 839
Barlow JF, 1243
Barnett TC, 1369
Bartels H, 825
Bartkowski-Dodds L, 925
Bartolucci AA, 725, 821, 1457
Barugel M, 149
Bast RC, Jr, 895
Basurto C, 1353
Baxter D, 571
Bedikian A, 611
Bekaert AB, 1279
Beker B, 733
Belasco JB, 323
Bender JF, 215
Benger A, 240
Bennett JM, 1439
Benson AB, III, 795
Berchtold W, 115
Berdeaux DH, 397
Berenzweig M, 21
Berger MR, 1415
Berkman AW, 161
Bertetto O, 695
Bertino JR, 279
Bertrand M, 725, 1335
Besner J-G, 275
Bever CT, 1342
Biblo LA, 1449
Billing R, 377
Birch R, 333, 1455
Birkhead BG, 595
Bischoff H, 1415
Bitran JD, 123
Bjornsson TD, 1383
Black M, 1015
Blackledge G, 801

Blackmore C, 483
Blackstein ME, 727
Bladé J, 923
Blayney DW, 1335
Bleyer WA, 1211
Blijham GH, 85
Block JB, 527
Blonk-v.d. Wijst J, 363
Blum RH, 167
Blumenschein G, 565
Bockman RS, 653
Bodey GP, 329, 611, 921, 1327
Bodurtha A, 941
Bogden AE, 717
Boiron M, 703
Bonadonna G, 965
Bonnet JD, 113, 1321
Bonneterre J, 79
Bonomi P, 1007
Booth BW, 919
Bork E, 1289, 1431
Borst J, 137
Boswell WD, Jr, 1031
Bosl GJ, 125, 459, 461
Boucher AE, 1003
Boutselis JG, 1329
Bowman WD, 355
Boyd MA, 1315
Boyer C, 129
Boyett J, 1425
Bozdech MJ, 377
Bozek T, 603
Brady J, 791
Bramwell VHC, 211, 339, 409
Brandes A, 17
Brandes LJ, 761
Braylan RC, 783
Brenner DE, 457
Brihi ER, 891
Brincker H, 5
Brindley CJ, 801
Brisebois B, 739
Brooks BJ, Jr, 244
Browman GP, 240
Brubaker LH, 313
Bruderman I, 733
Bruera E, 149, 751
Brynjolf I, 1342
Buchanan RB, 373
Budman DR, 719
Bull FE, 231
Bunin N, 236
Bunting N, 1007
Burchenal JH, 55
Burgess A, 565
Burke MT, 387
Burnett LS, 457
Burns CP, 153
Bury J, 1447
Buzdar AU, 1003
Buzzoni R, 965
Byar DP, 1055, 1339
Byfield JE, 645
Byrne PJ, 1365

C

Caballero GA, 13
Cadman EC, 133, 1441
Caillé P, 707, 901
Cain KC, 1139
Calciati A, 695
Caldarelli DD, 933
Calvert AH, 43
Camacho FJ, 21, 47, 451, 1033
Campbell MA, 833
Canaletti R, 1353
Canellos GP, 719, 1347
Cano J-P, 839
Canonico A, 241
Capizzi RL, 721, 897
Caponera M, 721
Caradonna R, 571
Caraveo J, 189
Carey RW, 919
Carlson RW, 903
Carr BI, 1335
Carr D, 344, 921
Carr DT, 921
Carraro S, 149, 751
Carter DC, 927
Carter WH, Jr, 1049
Case DC, Jr, 1315
Casper ES, 387, 591, 915, 1019, 1319
Cassileth PA, 61, 1439
Cassoni A, 1341
Catalano RB, 229, 1271
Cavalli F, 337, 1337
Cazellas P, 953
Cecchi G, 1335
Cedaro L, 149, 751
Cersosimo RJ, 1429
Cervantes F, 923
Chabner BA, 641
Chacón RD, 149, 751
Chan TCK, 425
Chang AY-C, 451, 1033
Chang M, 1451
Chatterji DC, 293
Chen TT, 113, 557, 583
Cheng E, 591, 1453
Chesney C, 315
Chiuten DF, 611, 921, 1327
Chlebowski RT, 527
Choi TK, 443
Christensen M, 236
Chun H, 179, 459, 461
Cibas IR, 387
Citron ML, 109, 735, 1325
Civin CI, 335
Clagett-Carr K, 1340
Clamon GH, 167
Clark MJ, 703
Clark RA, 1257

Clavel M, 337
Coates AS, 105
Coccia PR, 1211
Cohen AG, 565
Cohen LF, 403
Cohen MH, 109, 735, 1325
Coldman AJ, 1041
Coleman M, 61, 539, 689, 1027
Collins JM, 867
Colombo N, 1353
Comis RL, 127
Connors JM, 743
Cook RL, 91
Coombes RC, 351
Coonley CJ, 653
Cooper EH, 409
Cooper MR, 721, 897
Copeland LJ, 139, 1317
Costanza ME, 1387
Costanzi JJ, 113, 189
Coy P, 1241
Craig J, 897
Crawford ED, 189
Creagan ET, 141, 1451
Creaven P, 719
Creech RH, 229, 451, 1007, 1271
Crowther D, 225, 409
Cruz JM, 721, 897
Cserhati M, 115
Cullinan SA, 355, 1243
Cunningham D, 927
Curt GA, 641
Cuttner J, 1027

D

Daghestani AN, 61, 559
Dahl GV, 887
Dalton WS, 1309
Daniele O, 17
Daniels JR, 127
Danova M, 971
Dauber LG, 563
David R, 953
Davis TE, 795
Dayal H, 1271
Deboer G, 209
De Broe ME, 1279
Dedrick RL, 293
DeGraw JI, 551
De Gregorio MW, 1441
Deisseroth AB, 731, 1441
De Jager R, 707
deKernion JB, 263
Del Favero A, 1353
Deloux J, 953
Demaille A, 79
Deschamps M, 275
DeSimone P, 717
DeWys WD, 167
Dexeus F, 885
Dhingra HM, 921, 1327
Dick FR, 153
DiCostanzo F, 1353
Dierks K, 229, 1271
Dietrich M, 527
Diez B, 911
Dillon M, 457, 717
Dimitrov NV, 137
D'Incalci M, 69, 73
Diorio G, 275
Dixon DO, 577
Dodion P, 1387
Doll DC, 777
Dombernowsky P, 339, 1342
Donadio M, 695
Donahue JJ, 1195
Donati D, 1353
Donehower RC, 489, 1249
Doorenbos H, 977
Doppman JL, 293
Doroshow JH, 1335
Dorr RT, 431, 833
Douay L, 953
Dougherty JB, 559
Douglass HO, Jr, 543
Drake JC, 641
Drewinko B, 1023, 1391
Droz JP, 901
Ducret JP, 901
Duhamel G, 203, 953
Dukart G, 61
Dukeman M, 1305
Dunleavy S, 39
Durie BGM, 1369
Duroux P, 469

E

Edmonson JH, 141, 1243, 1451
Edwards RW, 153
Egan PC, 1387
Eggermont AM, 185
Egorin MJ, 795, 1387
Eguchi K, 945
Einhorn LH, 127, 333, 821, 1359
Einstein AB, 1253
Einzig A, 1453
Eisenberger MA, 319, 735, 1152
Eleff M, 867
Ellenberg SS, 1039, 1147, 1375
Ellison D, 725
Ellison NM, 65, 342
Elliot TE, 355
Elo HO, 1021
Emont E, 1335
Engstrom PF, 543
Enterline JP, 1249
Erickson C, 377
Erlichman C, 215
Esseese I, 1457
Estes NC, 1359

Estruch R, 238
Etcubanas E, 999
Ettinger DS, 451, 489, 1033
Ettinger LJ, 323
Evans AE, 323
Evans BD, 43
Evans WK, 167, 209, 227, 727
Everson LK, 355
Exten R, 377

F

Faintuch J, 123
Falletta JM, 1383
Falkson G, 755
Falkson HC, 755
Fanucchi MP, 55
Farina P, 73
Fay JW, 473
Fefer A, 791
Feld R, 167, 209
Ferme C, 703
Fernandez-Huerta JM, 238
Fetting JH, 1249
Feun LG, 329
Figlin RA, 263, 547
Filling-Katz MR, 1005
Finkel H, 369
Finkelstein DM, 451, 1033
Finkelstein JZ, 1331
Finlay JL, 377
Finley PR, 833
Fiore JJ, 591, 1257
Fiorentino MV, 17
Finn GP, 603
Fischmann B, 735
Fleming TR, 1243
Fletcher WS, 577, 709
Forastiere A, 457
Ford HT, 43
Fornasiero A, 17
Forrest GJ, 927
Fosser V, 17
Fossieck BE, Jr, 109
Foster BJ, 1340
Fowler R, 1241
Fox BM, 851
Fox JJ, 55
Fox RM, 105
Fram R, 587
Frank J, 189
Frankel SS, 645
Franklin R, 109
Franks D, 373
Franks PE, 867
Franzosi MG, 1353
Freedman RS, 1023
Frei E, III, 587
Freireich EJ, 611
Frenkiel S, 1015
Friedland M, 1001
Friedman B, 915
Friedman HS, 1383
Frimmer D, 711
Fritschi E, 1415
Fryer C, 1241
Fujita J, 945
Futami H, 945

G

Gaddipati J, 1001
Gail MH, 1107
Galindo A, Jr, 539
Gams R, 61, 1455
Garewal HS, 1309
Gasser AB, 225
Gasparini G, 965
Gasparini M, 211
Gastrointestinal Tumor Study Group, 417, 713
Geffen Y, 733
Gelber RD, 1139
Geller NL, 47, 1319
Gelman RS, 755, 1139
Gerard B, 337
Gershenson DM, 139, 1317
Giaccone G, 695
Gilchrist NL, 927
Giles GR, 1275
Gingrich RD, 153
Giovanella BC, 845
Girton ME, 293
Gisselbrecht C, 703
Glaubiger DL, 403
Glees JP, 43
Glicksman AS, 1199
Gockerman JP, 725, 1029
Goddard C, 801
Golbey RB, 459
Goldberg D, 1335
Goldberg J, 240
Goldberg RM, 813
Goldberg-Roberts R, 1271
Goldenberg GJ, 761
Goldie JH, 739, 769, 1041, 1241
Goldman ID, 867
Golomb F, 39
Goodhart LC, 43
Goodman A, 901
Gordon L, 1065
Gorin NC, 203, 953
Gottlieb A, 719
Gralla RJ, 387, 591, 711, 1257
Grañena A, 923
Grapski RT, 369
Gravenor D, 1015
Greco FA, 333, 457, 479, 821
Green AA, 439
Green SB, 1339
Green SJ, 355
Greenberg BR, 1369
Greig NH, 305

Gribble M, 143
Griffin JD, 787
Griffiths JC, 645
Grillo-Lopez AJ, 215
Grimaldi A, 961
Grochow LB, 1249
Groppe CW, 113
Grose WE, 577
Groshen S, 387, 1257
Grunberg SM, 1031
Gudauskas G, 119, 739, 1241
Guerra A, 25
Gupta RS, 515
Guy H, 703

H

Haanen C, 1447
Habboubi N, 891
Hadzic E, 1241
Haim N, 251
Hainau B, 1342
Hainsworth JD, 479
Hakes TB, 237, 559, 1319
Hall V, 373
Hammershaimb LD, 1177, 1263
Hammond D, 1211, 1331
Hande KR, 479
Handschumacher RE, 133
Hannigan JF, Jr, 143
Hansen HH, 339, 730, 1431
Hansen SW, 555
Harland SJ, 43
Harper GR, 1033
Harrell FE, Jr, 1071
Harris M, 39
Hartman G, 699
Harvey HA, 65, 127, 1003
Harvey JH, 1365
Harwood S, 109
Hattori K, 1433
Havsteen H, 1342
Hawkins RS, 341
Hayes DM, 1315
Hayes FA, 439
Hearn EB, 807
Hecquet B, 79
Heelan RT, 387, 711, 1305, 1453
Hellenbrecht D, 1301
Helms SR, 783
Henderson IC, 1003
Hendry WF, 483
Henne T, 1415
Herberman RB, 1161, 1165
Herman TS, 109
Herr HA, 47
Herrmann M, 1415
Herzig GP, 473, 881
Herzig RH, 473, 881
Hess WA, 733, 1342
Hicks WJ, 557
Higgins GR, 323, 699, 1331
Hilgers RD, 1329
Hillcoat BL, 562
Hirji K, 1399
Ho JHC, 761
Hochster H, 39
Hoffer SM, 1429
Hoffman FA, 167
Hogenkamp HPC, 453
Holcenberg JS, 403
Holden L, 801
Holinger LD, 933
Holleran WM, 1441
Holthuis JJM, 1279
Hong R, 377
Hong WK, 127, 1429
Hood L, 817
Hood MA, 1325
Hopkins HA, 25, 769
Hornbeck CL, 645
Horowitz M, 999
Horowitz SD, 377
Hortobagyi G, 565
Horton J, 571
Hortvet L, 259
Horvath C, 1443
Horwich A, 483
Hoshino T, 993
Hossan E, 885
Hoth DF, 199, 1177
Hottendorf GH, 875
Houghton JA, 91
Houghton PJ, 91
Howard J, 125
Howell A, 409
Howell SB, 205, 425, 657
Hrushesky WJM, 453
Hug V, 565
Hui SL, 1359
Huinink WTB, 337
Hunt J, 351
Hurson SB, 1263
Hurteloup P, 633
Hutchinson JC, Jr, 933
Hyde CM, 133

I

Ide T, 505
Iida H, 523
Iliadis A, 633
Imamura Y, 1433
Inamasu M, 557
Ingle JN, 355
Inoue K, 505
Irwin L, 1455
Isaacs M, 653
Iscoe N, 941
Isono N, 533
Issa P, 891
Issell BF, 127

Itri LM, 1031, 1399
Iven H, 825

J

Jackson DV, Jr, 721, 897
Jacquotte A, 469
Jaffe N, 1325
Jamin DC, 323, 699
Janaki L, 129
Jansen J, 953
Jeekel J, 185
Jefferies JA, 1243
Jehn U, 445, 1447
Johnson DE, 33
Johnson DH, 479, 821
Johnson JR, 1155
Johnson RJ, 409, 1275
Johnston-Early A, 735, 1325
Joneckis CC, 851
Jones G, 895
Jones HW, 457
Jonsson T, 730
Joss R, 1337

K

Kalman LA, 387
Kalwinsky DK, 315, 887
Kamen BA, 335, 403
Kao AK, 223
Kaplan S, 1337
Kaplan WD, 1347
Karakousis CP, 907
Karp DD, 1429
Kaufman J, 543
Kaufman RJ, 1319
Kavanagh JJ, 139, 1317
Keeney ED, 1023
Keller AM, 607
Kelsen DP, 387, 591, 711, 1257, 1305, 1453
Kemeny N, 179
Kempf RA, 1031
Kempson RL, 1207
Kennel SJ, 985
Kenny JB, 917, 1275
Kerbrat P, 901
Kerkhofs M, 1447
Kerr D, 47
Kessel D, 673
Khalyl MF, 891
Kidd P, 791
Kiel K, 933
Killackey MA, 237
Kimura K, 1433
King ME, 425
King OY, 1441
Kitchens CS, 1425
Klaassen D, 543
Klein FA, 47
Kleisbauer J-P, 839
Klimo P, 1241
Knapp RC, 895
Kochi M, 533
Koeller JM, 795
Koeffler HP, 1399
Kogut N, 1335
Koretz MM, 465, 903
Kornblith PL, 293, 733
Korzun AH, 919
Kovach JS, 97
Krailo M, 1211
Krakoff IH, 139
Kramer BS, 167, 333, 1425
Kramer T, 933
Krasnow SH, 109, 735, 1325
Krikorian JG, 369
Kris MG, 387, 1257
Krischer JP, 335
Krivit W, 1331
Kroner T, 115
Krook JE, 355, 1243
Kvols LK, 141

L

Laméris JD, 185
Land VJ, 335
Lane M, 729
Lanzotti VA, 127
Laporte JP, 203, 953
Laszlo J, 817
Lau WH, 761
Laurie F, 1199
Laurie JA, 355
Lawson RD, 127
Lazarus HM, 473, 881, 1449
Le Blanc G, 953
LeChevalier T, 469, 707
Leclaire R, 275
Lee KL, 1071
Leeser JE, 344
Lehane DE, 577
Leichman L, 1305
Leimert JT, 153
Leitner SP, 1319
Lemoine F, 203
Leonard RCF, 1347
Leong L, 1335
LePage DJ, 717
Leslie N, 587
Leveson SH, 1275
Lévi F, 1443
Levi JA, 105
Levin B, 123
Levin M, 39
Levin W, 235
Levitt M, 1115
Lewis B, 143
Leyland-Jones B, 55, 1235, 1340

Liance MC, 953
Licciardello JTW, 1429
Lightman SL, 1341
Lippman ME, 615
Lipton A, 65, 1003
Little JB, 769
Livingston RB, 583, 1313
Lockskin A, 845
Loehrer PJ, Sr, 1359
Logan T, 807, 1029
Logothetis CJ, 33, 885
Lokey JL, 687
Long HJ, 141
Longo DL, 1011
Longo W, 377
Look AT, 887
Looney WB, 25, 769
Lopez JA, 369
Lopez M, 953
Lowenberg B, 1447
Loynds P, 495
Lukens JN, 1211
Lumme PO, 1021
Lund B, 339
Lutz PJ, 91
Lynch G, 179

M

MacDonald W, 739
Macfarlane DK, 1177
MacIntyre JM, 543
Maddison K, 1409
Maekawa T, 505, 1433
Magee MJ, 125
Maggino T, 17
Magill G, 591, 1453
Maguire LC, 153
Maguire ME, 787
Mailhot S, 275
Mailliard JA, 1243
Makuch RW, 167
Malcolm A, 587
Maldazys J, 263
Maley WV, 917, 1275
Malkasian GD, 1243
Maluish AE, 1165
Mamaril AP, 539
Mancuso L, 241
Mangioni C, 69, 73
Mann J, 369
Marchi S, 241
Margarino G, 961
Margolese R, 1015
Margolin K, 1335
Markman M, 161, 205, 341
Maroun JA, 127, 269
Marquet RL, 185
Marschke RF, 355
Marsh JC, 683, 1033
Marsoni S, 1235, 1263
Martelo O, 807
Marti C, 115
Martin DS, 179, 421
Martin G, 924
Martin M, 469, 839
Marty M, 703
Masaoka T, 1433
Matchar DB, 1071
Mathé G, 1443
Mauer JK, 1177
Mauriac L, 633
Mayer RJ, 787
May-Levin F, 707
McArdle CS, 927
McClain CJ, 1437
McCormack GW, 355, 1243
McCracken JD, 129, 709
McFadden M, 1365
McFarlin DE, 1342
McIntyre OR, 331
McKenzie M, 1325
McKinney S, 1127
McKneally MF, 571
Mechkouri M, 1443
Mekori T, 251
Mellink WAM, 85
Meloche S, 275
Mendoza JT, 845
Merlano M, 961
Merlini G, 971
Messeih AA, 1003
Meulenberg PMM, 85
Meyer WH, 236
Meyers FJ, 143
Meynadier J, 79
Meyskens FL, Jr, 397, 1369
Mɔzger J, 445
Michaelson RA, 1019
Middleton J, 373
Miller AB, 761
Miller DR, 1211
Miller TP, 1313
Mintzer DM, 711
Mirro J, Jr, 315, 887
Misawa S, 505
Mitchell E, 143
Mitchell JB, 1293
Mitchell MS, 1031
Mittelman A, 1001
Miura Y, 1433
Miwa S, 1433
Miyazaki T, 1433
Mizoguchi H, 1433
Moen R, 377
Moisan R, 275
Momparler R, 699
Mondesir JM, 707, 901
Monges J, 911
Montecucco C, 971
Montella D, 499
Montserrat E, 238, 923
Moon TE, 397

Moore MR, 1457
Moran EM, 167
Moreno I, 909
Morsia D, 1353
Mortensen SA, 730
Muggia FM, 39, 223
Muindi J, 351
Multhauf P, 725, 1335
Munson J, 137
Muriel FS, 911
Murphy S, 315
Murphy WK, 921
Murray N, 723, 1241
Murray R, 1003
Murthy AK, 933
Musella R, 695
Muss HB, 721, 897

N

Nagashima T, 993
Nagel GA, 1003
Najman A, 203, 953
Nassif E, 369
Natali PG, 985
Neefe JR, 813
Neidhart JA, 215
Nervi C, 25
Neville AM, 351
Newcomer LN, 607
Newlands ES, 801
Newman DR, 341
Ng A, 443
Nguyen-Ngoc T, 633
Nicoletto O, 17
Nicoll J, 1341
Niloff JM, 895
Nitschke R, 335
Nitta K, 285
Niwayama M, 533
Nomura T, 1433
Norton L, 719
Noyes WD, 1425
Nundy D, 269

O

Oblon DJ, 783, 1425
Obrecht JP, 719, 1337
O'Bryan RM, 189, 557, 583, 709
Ochoa M, Jr, 591
O'Donnell MR, 571
O'Dwyer PJ, 1340
Oettgen HF, 47
O'Fallon JR, 141, 1101
Oguro M, 1433
Ohno R, 1433
Ohta K, 1433
Oishi N, 129, 557
Oldfield EH, 293
Olman EA, 795
Olshen RA, 1065
O'Malley S, 409
Omura GA, 807, 1457
O'Reilly W, 1007
Orr DW, 489
Osamura S, 1433
Osoba D, 727
Ottema B, 209
Otter GM, 551
Owens SE, 1275

P

Paccagnella A, 17
Page JP, 105
Panasci LC, 919, 1015
Panettiere FJ, 113, 231
Paquette-Tello DA, 1429
Parente R, 1019
Parks SF, 663
Parmar H, 1341
Parmiani G, 219
Pasmantier MW, 539, 689
Passalacqua R, 1353
Paterson A, 941
Patterson RH, 735
Paulson DF, 663
Peckham MJ, 483
Pecora M, 687
Pederson DF, 449
Peetermans M, 1447
Pennington K, 1359
Perez D, 351
Perrier DG, 833
Perry DJ, 199
Peterson A, 377
Pezzoni G, 219
Pfeifle CE, 205
Pfeifle DM, 355
Phillips GL, 473, 881
Phillips RH, 1341
Piantadosi S, 1055
Picozzi VJ, Jr, 903
Pierce VK, 237
Pierson HF, 1283
Pikler GM, 127
Pinsky CM, 47, 1171
Pinto JEB, 859
Piotti P, 965
Plager JE, 907
Planting AST, 363
Podratz KC, 1243
Politi PM, 149, 859
Poncelet P, 953
Pool B-L, 1415
Porter LL, III, 479
Powell B, 897
Powles TJ, 351
Pratesi G, 219

Pratt CB, 236, 403
Preisler HD, 195, 240
Presant CA, 807, 821, 1335
Prior J, 269

Q

Quebbeman EJ, 13
Quiguyan CC, 539
Quirt I, 941

R

Ragaz J, 1003
Rahmani R, 839
Rainey JM, 583
Raney M, 807, 1029
Rapoport SI, 305
Rappaport D, 1335
Ravry MJR, 1457
Raymond V, 559, 1319
Raza A, 195
Read EJ, 769
Reavis K, 721
Reichert TA, 1071
Reinberg A, 1443
Reinstein LE, 1199
Remagen W, 115
Renard J, 339
Rentschler RE, 127
Reville B, 925
Ribas-Mundo M, 909
Riccardi A, 971
Rice AP, 489
Richards F, II, 721, 897
Rieber E, 1001
Righini R, 25
Rio B, 953
Rivkin SE, 1035, 1329
Robert F, 215
Robert J, 633
Robin E, 123
Robinson BA, 43
Robinson E, 251
Roca E, 149, 751
Roelofs R, 453
Rohrbaugh TM, 323
Roila F, 1353
Rootman J, 119
Rørth M, 449
Rosell R, 909
Rosen NL, 561
Rosenbaum C, 499
Rosenbaum PF, 127
Rosenshein NB, 457
Roses D, 39
Ross DD, 851
Ross DD, 851
Ross R, 1425
Rosso R, 961
Rothlin RP, 859
Rouëssé JG, 211, 469, 707, 901
Roulon A, 1443
Roviaro G, 69
Rozencweig M, 211, 337, 1339
Rozendaal KY, 1447
Rozman C, 238, 923
Ruccione KS, 323
Ruckdeschel JC, 21, 571, 1007, 1033
Rudolph RH, 1253
Russel JA, 211
Russell J, 941
Russo A, 1293
Rutledge FN, 1023

S

Sacchi A, 985
Saijo N, 945
Saiki JH, 113
Saito Y, 1297
Sakai Y, 1433
Sakurai Y, 523
Salem PA, 891
Salinas FA, 743
Saller R, 1301
Salmon C, 953
Salvagno L, 17
Samuels ML, 33, 885
Sánchez-Durán A, 924
Sancho-Garnier H, 469, 707
Santen RJ, 1003
Sanz MA, 924
Sarna GP, 263, 547
Sasaki Y, 945
Satzinger G, 1415
Saul PB, 139, 1317
Savaraj N, 329
Sawyer RC, 421
Scarffe JH, 225, 495, 917, 1275
Schaetzl EM, 895
Schally AV, 1341
Scharschmidt LA, 563
Scherokman B, 1005
Schiffer CA, 1027
Schipper H, 1115
Schmähl D, 1415
Schmid FA, 551
Schneider D, 1383
Schnetzer GW, III, 607
Schoch I, 61
Schold SC, 1383
Schwartz PM, 133
Schwen M, 499
Scoppetuolo M, 1319
Segal R, 251
Seifter EJ, 244, 1011
Selig DE, 33
Servi RJ, 342
Sessa C, 69, 73, 1337

Sethi VS, 729
Sexauer JM, 607
Shachor J, 733
Shah A, 723, 739, 1241
Shah MK, 229, 1271
Sharp TR, 645
Sheidler VR, 1249
Shelley W, 941
Shepard KV, 123
Shepherd FA, 209, 727
Shihabi Z, 729
Shildt R, 709
Shimizu E, 945
Shimoyama M, 1433
Shinkai T, 945
Shirakabe K, 533
Shoemaker RH, 683
Shore NA, 699, 1331
Showell JL, 933
Siegel SE, 323, 699, 1211
Siegenthaler P, 1337
Siemann DW, 1409
Sikic BI, 465, 903
Silber R, 1033
Silberman HM, 807
Sileni VC, 17
Silgals R, 813
Silver HKB, 723, 743
Silver RT, 61, 539, 689
Simon RM, 1, 1039, 1087, 1235, 1263, 1375
Simmonds MA, 65
Singh T, 137
Sirotnak FM, 551
Skarin AT, 587, 1347
Skovsgaard T, 555
Slack JA, 801
Slagel DE, 717
Sleijfer DT, 977
Slevin ML, 603
Sluiter WJ, 977
Smallwood J, 373
Smith DB, 917
Smith FE, 729
Smith IE, 43
Smith JA, Jr, 189
Sobrero AF, 279
Soifer I, 561
Somers R, 211
Sondel PM, 377
Sonoda Y, 505
Sordillo PP, 1019, 1453
Sørensen JB, 555
Sørensen PG, 1431
Souhami RL, 603
Soukop M, 927
Southern California Leukemia Group, 1399
Speyer J, 39
Spielmann M, 707, 901
Spitzer G, 921
Spitzer TR, 473, 1449
Spurr CL, 721, 729, 897
Stachowiak J, 953
Stanton GF, 915, 1019
Staquet MJ, 1339
Stehlin JS, Jr, 845
Steinberg JP, 687
Stephens RL, 189, 231, 709, 1035, 1321, 1329
Sternberg CN, 343, 1305
Stevens MFG, 801
Steward WP, 225
Stewart DJ, 269, 329
St. Marie K, 229
Stockdale A, 1341
Stolbach L, 1007
Stolfi RL, 421
Stone A, 431
Stott P, 137
Strauman JJ, 561
Stryckmans P, 1447
Stuart JJ, 721, 897
Stuckey WJ, 577
Subramanian VP, 709
Suffness M, 683
Svingen PA, 97
Sweeney DJ, 305
Sweet DL, 123
Swindell R, 409
Sylvester R, 211

T

Taetle R, 425
Takaku F, 1433
Takeuchi M, 285
Takino T, 505
Tanaka T, 285
Taniwaki M, 505
Tannock IF, 227, 1127
Tatarek R, 961
Tattersall MN, 105
Taylor D, 727
Taylor KM, 1095
Taylor SG, IV, 755, 933
Taylor W, 817
Tell D, 1005
Temple R, 1155
Tetreault L, 269
Tew KD, 677
Thatcher N, 409
Theodore C, 901
Thomas D, 211
Thomas DGT, 603
Thompson JA, 791
Tipping S, 457
Tirindelli D, 25
Tognoni G, 1353
Tominaga K, 945
Tonato M, 1353
Tormey DC, 755, 795
Torti FM, 143
Tredese F, 17
Trigg ME, 377
Trugman J, 453

Trump DL, 259, 795
Tsuda S, 505
Tsukagoshi S, 523
Tsuruo T, 523
Turbow MM, 465
Turek PJ, 133
Tyson LB, 1257

U

Ucci G, 971
Uchino H, 1433
Umsawasdi T, 921, 1327
Ungerleider RS, 403, 1263
Urba WJ, 244
Urbano-Márquez A, 238
Urso R, 73
Uzuka Y, 1297

V

Valdivieso M, 611, 921, 1327
Van Deijk WA, 85
Van de Vyver FL, 1279
Vannicola P, 369
van Oort WJ, 1279
van Oosterom A, 211
van Putten WLJ, 363
van Veelen H, 977
Varini M, 115
Vats T, 335
Velez-Garcia E, 215
Venturi CL, 1031
Verleun H, 1279
Veseley Z, 251
Vietti TJ, 403
Villani F, 965
Vinceguerra M, 1019
Vinciguerra V, 331
Viviani S, 965
Vogel R, 999
Vogl SE, 21, 1007
Vogler WR, 807
Voisin GA, 953
von Eschenbach AC, 885
Von Hoff DD, 231, 543, 1329
Voss N, 1241
Voûte PA, 211
Vreeland F, 109
Vrignaud P, 633
Vugrin D, 817

W

Wagener T, 211
Wagstaff J, 225, 495
Walker IR, 240
Wall C, 761
Wallace S, 33
Walther PJ, 663
Wampler GL, 127, 867
Wang AL, 677
Ward M, 351
Ware JL, 663
Warneke C, 845
Warr D, 1127
Warrell RP, Jr, 653
Watanabe KA, 55
Waterfield WC, 161
Watson PR, 313
Weatherall TJ, 129
Webb KS, 663
Weck P, 315
Weick JK, 583
Weiden PL, 1253
Weiershausen U, 1415
Weimar W, 185
Weiner J, 1211
Weiner RS, 167, 783, 1425
Weiselberg L, 559
Weisenthal LM, 615
Weiss RB, 199, 777, 919
Welander C, 721
Wernz JC, 127, 223
Westlake D, 607
Wharton JT, 1317
Whisnant J, 315
White DR, 721, 897
White DS, 65
Whitmore WF, Jr, 47
Wickes AD, 657
Wiernik PH, 457, 561
Wilber BJ, 1441
Wilber JR, 1441
Wilberding C, 673
Wilcox PM, 1249
Willemse PHB, 977
Willemze R, 1447
William L, 143
Williams CJ, 373
Williams PD, 875
Williams SD, 1359, 1455
Wilson K, 723, 1241
Windschitl HE, 355, 1243
Winn RJ, 1319, 1453
Winton EF, 807
Witte RS, 795
Wittes RE, 1, 125, 769, 1039, 1177, 1235, 1375
Wolf K, 1409
Wolff SN, 473, 881
Wolter JM, 1033, 1189
Wong DC, 731
Wong J, 443
Wood WC, 919
Woods RL, 105
Woolley PV, 1365

Y

Yaghmai F, 313

Yagoda A, 343
Yamada K, 1433
Yang L-Y, 1391
Yarnold J, 43
Yeager RL, 293
Yoshida Y, 1433
Young B, 425
Young CW, 55, 179, 421, 1319
Young JA, 607
Young RC, 1011
Young V, 941
Yung W-KA, 329

Z

Zekan PJ, 721, 897
Zidar BL, 1035
Zittoun R, 953, 1447
Zucchetti M, 73